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CHAPTER 1 INTRODUCTION
Despite enormous investments in research and development (R&D), it still takes approximately $800 million to $2 billion and 10-17 years to approve a new drug for clinical
use [5, 67, 68]. More than 90% of drugs fail to pass beyond the early stage of development and toxicity tests, and many of the drugs that go through early phases of the clinical
trials fail because of adverse reactions, side effects, or lack of efficiency. Based on a recent report [244], around 90% of drugs are effective only on 40% of patients, and such
ineffective treatment can cause an enormous loss ($350 billion/year) in the United States
alone.
We are addressing above mentioned challenges by introducing two main strategies.
First, we are developing a novel computational method to discover novel therapeutic roles
for existing FDA-approved drugs. The identification of novel disease indications for approved drugs, known as drug repositioning (or repurposing), is a very effective way to
increase the therapeutic arsenal at a very reduced cost [16, 42, 54, 173, 205, 232, 238,
239, 292]. Finding new disease indications for existing drugs sidesteps all these issues
and can therefore increase the available therapeutic choices at a fraction of the cost of a
new drug development. The need for new drugs is currently met mostly with the classical
drug development pipeline, which is slow, extremely expensive, and very prone to failures.
Drug repurposing tools are likely to be widely adopted by pharmaceutical companies because they would offer a very low cost solution to increase the market size for their existing
drugs [167, 237]. The societal impact includes increasing the available therapeutic choices
for existing diseases, reducing treatment cost by offering more alternatives, as well as possibly finding treatments for “orphan diseases” - rare diseases that will never have targeted
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drugs because they do not justify the usual drug development cost for their market size.
In this thesis, new usages for existing FDA-approved drugs are identified by performing
a system-level analysis using gene expression data and publicly available data, including
drug targets, disease-associated genes and KEGG signaling pathways.
Analyzing the diversity and evolution of single cancer cells can also enable the advances in early cancer diagnosis, and ultimately choosing the best strategy for cancer
treatment [149, 231, 244]. In particular, this analysis can play a crucial role in cancer
treatment, where individual cells develop drug resistance and metastasis [122, 136, 244].
Recent advances in single-cell RNA-Seq (scRNASeq) techniques have provided transcriptomes of the large numbers of individual cells (single-cell gene expression data) [61,
79, 99, 126, 168, 186, 194, 266, 280]. Unlike the bulk measurements that average the
gene expressions over the individual cells, gene measurements at individual cells can be
used to study several different tissues and organs at different stages [99, 126, 186, 266,
280]. Furthermore, one important analysis on scRNASeq is the identification of cell types
that can be achieved by performing an unsupervised clustering method on transcriptome
data [12, 13, 75, 177, 291, 304, 308].
In this thesis, as a second strategy, we have introduced a novel method to identify the
cell types using single-cell gene expression data. To do this, we have developed a pipeline
to cluster the individual cells based on their gene expression values such that each cluster
consisting of cells with specific functions or distinct developmental stages. We used the
Adjusted Rand Index (ARI) [113], adjusted mutual information (AMI) [274, 275], and
V-measure [226] to evaluate the performance of the clustering result for datasets in which
the true cell types are known.
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This thesis is organized as follows. Chapter 2 focuses on the proposed approach for
drug repurposing, introduced in the context of the systems biology. In this approach, new
usages for existing FDA-approved drugs are identified by performing a system-level analysis using gene expression data and publicly available data, including drug targets, diseaseassociated genes and KEGG signaling pathways. The proposed approach first builds a
drug-disease network (DDN) by considering all interactions between drug targets and
disease-related genes in the context of signaling pathways [205]. This network is integrated with gene-expression measurements to identify drugs with new desired therapeutic
effects. This method is evaluated based on its ability to re-discover drugs that are already
FDA-approved for a given disease.
Our approach is innovative because it focuses on the effect at the pathway level, rather
than the effect on a specific set of genes. Cancer could be used as a good high-level example [63]. One of the “hallmarks” of solid tumors independently of the type of cancer
or localization is that the cancer cells manage to avoid apoptotic signals. In other words,
their apoptotic pathway is inhibited. The specific set of genes that each particular type
of tumor uses to accomplish this is less relevant than the ultimate effect, which is uncontrolled proliferation. Identifying the specific genes that are dis-regulated in a given type
of tumor and then looking for drugs that have an antagonistic effect on the very same
set of genes, as proposed by Sirota et al. [248] is a sufficient but perhaps not necessary
condition. Identifying a drug that has an antagonistic effect on the apoptotic pathway may
be sufficient, even though this drug may induce its effect through a different set of genes
than that used by the tumor to escape apoptosis in the first place.
Chapter 3 focuses on recent methods for the identification of cell types based on un-
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supervised clustering of the single cell gene expression data. In this chapter, we propose
a framework that addresses challenges in identifying meaningful clusters of cells. We
validate the performance of the proposed method on eight publicly available scRNA-seq
datasets with known cell types as well as five simulation datasets with different degrees of
the cluster separability. We compare the proposed method with five other existing methods: RaceID [93], SC3 [139], SINCERA [95], SEURAT [162], and SNN-Cliq [291]. The
results show that the proposed method performs better than the existing methods. Finally, chapter 4 concludes the dissertation by proposing future work and possible research
directions.
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CHAPTER 2 DRUG REPURPOSING
2.1

Problem statement
Despite enormous investments in research and development (R&D), it still takes ap-

proximately $800 million to $2 billion and 10-17 years to approve a new drug for clinical
use [5, 67, 68]. More than 90% of drugs fail to pass beyond the early stage of development and toxicity tests, and many of the drugs that go through early phases of the clinical
trials fail because of adverse reactions, side effects, or lack of efficiency. Indeed, the rate
of failure is still significantly higher than the rate of approval [31, 67, 68]. In order to
overcome these challenges, drug repurposing, an approach aiming to find new indications
for existing drugs [54], has emerged as an important strategy for drug discovery [16]. This
approach can also rescue drugs that are safe but fail to get to market due to the lack of
efficacy against their initial clinical indication [58]. A well-known example of repurposed
drug is Thalidomide. Originally, this drug was approved for the treatment of morning sickness during pregnancy. Not long after that, it was withdrawn from the market due to the
severe birth defects in the early 1960s [135]. However, several years after, it was approved
by the FDA for the treatment of multiple myeloma [20].
2.2

Overview of existing approaches
Repurposing approaches can be categorized as drug-based or disease-based. Disease-

based approaches are developed to overcome the lack of knowledge about the pharmacology of a drug [41, 74]. Drug-based approaches are preferred when drug data (e.g.
transcriptomic data) are available. While each one of these approaches faces several challenges, successful repurposing approaches often take advantage of both drug and disease
data. In this area, a number of of approaches have been developed based on the analysis
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of transcriptomic data, such as gene expression signatures, defined as the changes in the
expression of genes under a certain condition (e.g. administration of a drug, or a disease). Some of these approaches are based on the idea that if there is an anti-correlation
between a drug-exposure gene expression signature and a disease gene expression signature, that drug may have a potential therapeutic effect on the disease [146, 248]. Drugs
that are strongly anti-correlated with a disease are likely to be candidates for repurposing.
Resources such as LINCS (new version of Connectivity Map [146]) allow for systematic
search of candidates for drug repurposing.
The Connectivity Map (CMap) project [146] was the first systematic approach aimed
at exploring functional connections between drugs, as well as between drugs and diseases.
This project led to the first repository of genome-wide expression data from five human
cancer cell lines exposed with 1,309 compounds at different dosages, and integrated with
other sources such as NCBI Gene Expression Omnibus (GEO). [146] evaluate the similarity of a query signature, that can be a drug-exposure gene expression signature or a
disease gene expression signature, to each drug signature in Connectivity Map database
(reference data). In [248] the authors developed a systematic approach based on the same
idea originally proposed by [146]. In this work, they use drug-exposure gene expression
signature from Connectivity Map as the reference data and query this reference data with
every single disease gene expression signature by applying a pattern-matching method.
Some approaches [49, 116, 198] employ Over-Representation Analysis (ORA) in order
to understand the mode of actions (MoA) of drugs and their potential new usages. The
most recent approach [116], DGE-NET, is based on the hypothesis that drugs with similar
binding patterns (to a reference target protein) have similar molecular activities. In step
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1, drug-target interactions (drug-target signatures) are predicted. DGE-NET ranks drugs
that most likely bind to a given target based on similarity scores between different drugs
and the given target. To do this, a modified version of Train, Match, Fit and Streamline
(TMFS) [62] is used. TMFS determines the binding potential of a protein-ligand complex
incorporating docking, three-dimensional shape, and ligand physicochemical data. For a
given protein target, the top 40 drugs (1% of all drugs) are selected as hits for the next
step. In step 2, the associations between the drug-target signatures on the one hand,
and diseases, pathways, functions, and protein-protein interactions on the other hand, are
identified. To this end, a hypergeometric test is applied at different biological levels: protein targets, protein-protein interactions (PPIs), cell signaling pathways, and molecular
functions. In this step, gene expression data of the given disease is exploited to identify
differentially expressed genes by comparing the expression values of two groups of samples: normal and disease. DAVID [110, 111] and STRING analysis [80] is applied on the
list of differentially expressed genes to indicate the associations at different levels (by computing z-scores). The identified associations are validated based on the current literatures
and annotated databases. DGE-NET is applied to human disease gene expression datasets:
rheumatoid arthritis, inflammatory bowel disease, Alzheimer’s disease, and Parkinson’s
disease to prioritize FDA-approved drugs for repurposing purposes.
Another approach [198] performs the pathway enrichment analysis to investigate MoA
and clinical functions of the FDA-approved drugs. First, it selects sixteen FDA-approved
drugs (with available target information) from DrugBank [287]. Then, it retrieves primary
and secondary targets of these drugs from GEO datasets [76], MMDB [164], and PubChem [153]. And finally, it applies the enrichment analysis based on a modified Fisher’s
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Test using the drug targets and pathways data. Pathways are ranked based on the numbers of retrieved drug targets involved in each pathway. Pathways with p-values <0.05 are
chosen for further investigations.
The third method using an ORA approach analyzes the associations among drugs,
targets and biological functions [49]. It assigns drugs into nine classes based on their
targets: (1) G protein-coupled receptors, (2) cytokine receptors, (3) nuclear receptors,
(4) ion channels, (5) transporters, (6) enzymes, (7) protein kinases, (8) cellular antigens and (9) pathogens. Then, it employs an enrichment analysis to identify the associations between the drugs and features including GO terms [17] and KEGG (http:
//www.genome.ad.jp/kegg/) pathways. Thus, given the drug and the KEGG pathway (or
GO term), an enrichment score is computed as S_KEGG (or S_GO) based on the result of
hypergeometric test (p-value). Overall, 279 KEGG pathways and 17,904 GO terms are exploited to obtain the enrichments scores. Each drug is represented by 279 S_KEGG enrichment scores and S_GO 17,904 enrichment scores. Finally, the feature selection minimum
redundancy maximum relevance (mRMR) method [203] is used to extract the key features. Pathways and GO terms that are highly enriched by several classes of drugs can be
investigated for drug interaction predictions. For instance, the neuroactive ligand-receptor
interaction pathway is enriched with two classes: GPCR and IC. This suggests that drugs
with different targets may belong to the same biological pathway, thus also suggesting a
potential for synergistic drug interactions.
The lack of a unifying analysis at system-level makes such ORA methods limited. In this
study, we use: i) KEGG signaling pathways, ii) drug target data, and iii) disease associated
genes to construct a global network with genes specific to the drug and disease of inter-
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est (called drug-disease network, DDN). We then measure gene perturbation signatures
for drug-disease pairs by propagating measured expression changes across the network
topology.
Methods based on protein-protein interactions that employ over-representation analysis (ORA) are limited by the fact that each gene is analyzed independently without a
unifying analysis at a system level, while the proposed approach aims to consider the
system-level dependencies and interactions on the drug-disease-specific network. One of
the existing approaches for drug repurposing is based on an over-representation analysis
of various pathways, based on the genes targeted by a given drug [116]. Based on this approach, a drug is first associated with pathways based on its directly targeted genes. Using
this approach, Sunitinib can be associated to the following KEGG pathways: MAPK signaling pathway, Cytokine-cytokine receptor interaction, VEGF signaling pathway, and Pathways
in cancer. Subsequently, Issa et al. expand the set of genes to include the genes having
direct interactions with the Sunitinib target genes using PPI data, and recalculated the
pathways enriched in these “predicted targets”. Table 1 shows the list of pathways that are
significantly enriched in such predicted targets (FDR-corrected p-values less than 0.05).
Although this type of ORA analysis could provide useful associations between Sunitinib
and various pathways, extrapolating from pathways to diseases may not be optimal since
there are many diseases that might be relevant to these pathways. For instance, the KEGG
pathway Pathways in cancer is associated with over 1,000 diseases according to CTD [169].
This illustrates why this simple pathway-based enrichment approach cannot be used for
effective drug repurposing and explains why our system-level analysis is able to provide
much more specific results.
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Table 1: A list of pathways that are significantly enriched in predicted target genes for
Sunitinib (FDR-corrected p-value < 0.05).
Pathway
PI3K-Akt signaling pathway
Cytokine-cytokine receptor interaction
Focal adhesion
Pathways in cancer
Melanoma
Prostate cancer
mTOR signaling pathway
Gap junction
MAPK signaling pathway
Glioma
HIF-1 signaling pathway
Endocytosis
Pertussis
Regulation of actin cytoskeleton
Rheumatoid arthritis
Transcriptional misregulation in cancer
Amoebiasis
Legionellosis
Acute myeloid leukemia
p53 signaling pathway
Long-term potentiation
Hepatitis B
HTLV-I infection
Hypertrophic cardiomyopathy (HCM)
Progesterone-mediated oocyte maturation
Calcium signaling pathway
Oocyte meiosis
Osteoclast differentiation
Amyotrophic lateral sclerosis (ALS)
Insulin signaling pathway

pORA.fdr
1.08E-18
1.11E-15
2.80E-14
1.20E-12
1.75E-07
8.30E-07
1.08E-06
1.29E-05
3.73E-05
3.73E-05
3.73E-05
0.00088
0.00093
0.00093
0.00174
0.00317
0.00468
0.00638
0.00747
0.00904
0.00943
0.00982
0.01044
0.01341
0.01341
0.01605
0.02104
0.04606
0.04606
0.04798

In summary, the limitations of these methods can be summarized as follows: i) the
obtained target proteins might not be the exact target of a drug (for instance, they can
be indirectly associated to the drug because of down or upstream proteins or cross-talk
effects); ii) the target(s) of a drug have a limited ability to identify the pathways based
on enrichment alone since one or a few genes on a pathway are unlikely to constitute
sufficient statistical evidence; iii) the drug targets might be involved in variety of pathways
that are not specifically related to the drug primary target. Thus such methods may fail in
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identifying significant pathways related to biological functions of the drug based on their
target information.
Although existing drug repurposing methods showed moderate success, they are far
from bringing critical advancements in the drug development pipeline. Most of these
approaches rely only on an analysis of a set of differentially expressed genes. However, changes in genes expression are propagated in the system through a complex gene
signaling network and this fact is not captured by approaches using only lists of DE
genes [72, 133, 180].
It has been shown that many drugs exert their effect through modulation of several proteins rather than single targets [105, 106, 196, 217]. Furthermore, the analysis by [300]
shows that not all drugs directly impact the proteins associated with the root cause of a
disease. These findings suggest that drug repurposing may be more successful if it used
novel paradigms, going beyond lists of genes.
Systems biology can be used as an effective platform in drug discovery and development by leveraging the understanding of interactions between the different system components [3, 14, 34, 60, 141, 205, 259, 260, 270, 297]. In this work, we propose a systems
biology approach that takes advantage of prior knowledge of drug targets, disease-related
genes, and signaling pathways to construct a drug-disease network (DDN) composed of
the genes that are most likely perturbed by a drug [205]. By performing a system-level
analysis on this network using disease gene expression signatures and drug-exposure gene
expression signatures, our approach estimates the amount of perturbation caused by a
drug on the genes that are associated to a disease of interest. Drugs are ranked based
on the amount of perturbation they exercise on specific disease-related genes, and highest
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ranking drugs are proposed as candidates for repurposing.
We compare the results of our approach with the computational drug-repurposing approach proposed by [248] using 19 datasets involving 4 diseases: idiopathic pulmonary
fibrosis (IPF), non-small cell lung cancer (NSCLC). We show that our approach provides a
more accurate prediction based on its ability to identify drugs that are already approved
for the disease of interest.
2.3

Drug repurposing using systems biology

2.3.1

Disease and drug gene expression data

Large scale drug-exposure gene expression data are obtained from two databases: Connectivity Map and the Library of Integrated Network-Based Cellular Signatures (LINCS) [146]
(http://www.lincsproject.org/).
Disease expression data are obtained from NCBI Gene Expression Omnibus (GEO) [76]
and Lung Genomics Research Consortium (http://www.lung-genomics.org).
In Connectivity Map, drug expression data are measured from the exposure of 5 human
cell lines to bioactive small molecules. Differentially expressed genes (DEGs) are identified using a moderated t-test [250] by comparing treated samples and the corresponding
control (untreated) samples. The resulting p-values are FDR adjusted [24] to correct for
multiple comparisons.
The LINCS program, the successor of CMap [146], generated transcriptional gene expression data from cultured human cells exposed to small molecules and knock-downoverexpression of a single gene. The data is also available in GEO (GSE70138). This
program provides DEGs in terms of z-score signatures by comparing two groups of samples (treatment vs control). Since measurements are carried out on different platforms,
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we standardize gene identifiers from chip specific probe identifiers to NCBI GeneID identifiers using the affy package [83]. We average across distinct probe expression values when
multiple probes mapped to the same NCBI GeneID.
In both Connectivity Map and LINCS, there are often more than one replicate for each
drug. Replicates with at least (1%) DEGs (FDR-adjusted p-value <0.025) are selected.
Since measurements are carried out on different platforms, we standardize gene identifiers
from chip specific probe identifiers to NCBI GeneID identifiers using the affy package [83].
We average across distinct probe expression values when multiple probes mapped to the
same NCBI GeneID.
We use two sources: i) Connectivity map (CMap) [146] for breast cancer and prostate
cancer, and ii) NIH’s Library of Integrated Network-based Cellular Signatures (LINCS) for
idiopathic pulmonary fibrosis (IPF) and non-small cell lung cancer. We used two different
data sources in order to show the approach is reliable and works independently of the
source of the drug data. CMap database has several of FDA-approved drugs for breast
cancer and prostate cancer but none for idiopathic pulmonary disease (IPF). So, for IPF
we used LINCS database that has several gene expression profiles for Nintedanib (an FDAapproved drug for IPF). We chose to use LINCS for non-small cancer (NSCLC) rather than
CMap for two reasons. First, more FDA-approved drugs belong to this database. (four drug
instances for each of FDA-approved drugs: Gefitinib and Crizotinib). In comparison, the
only FDA-approved drug for NSCLC in CMap is Paclitaxel and there is only one instance
for this drug. Second, in LINCS, 123 out of 260 drug instances are measured on the
A549 cell line that is the human lung adenocarcinoma epithelial cell line (a model For
NSCLC). Since IPF is a chronic progressive and ultimately fatal disease that did not have
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any effective treatment until recently, we were interested to see if our proposed approach
is able to predict any new treatments for this disease.
2.3.2

Drug-targets and disease-related genes

The proposed approach needs to construct a network that includes all the shortest
paths between the drug targets and genes known to be associated to the disease of interest. Drug targets and disease-related genes (genes associated with the disease of interest) are retrieved from the Comparative Toxicogenomics Database (CTD) [169] and
Drugbank [287]. CTD is a database that provides curated data describing cross-species
chemical-gene/protein interactions and gene-disease associations. Drugs with no known
targets are removed from the study. Such drugs are mostly not FDA-approved.
2.3.3

Signaling pathways

We obtain signaling pathways from Kyoto Encyclopedia of Genes Genomics (KEGG)
(http://www.genome.ad.jp/kegg/). A signaling pathway in KEGG is modeled by a graph
in which nodes represent genes or proteins, and directed edges between them represent
signals between genes or proteins. The edges are weighted based on the various types of
signals, such as activation, inhibition, etc.
2.4

Proposed framework

2.4.1

Drug-disease network construction

The first part of the framework consists in building the drug-disease network (DDN)
by integrating knowledge about the disease-related genes, drug targets, and gene-gene
interaction knowledge. Then, a repurposing score is computed for each drug-disease pair
by integrating expression data into this network. Figure 1 represents the proposed framework. As shown in Figure 1A, first, we construct a global network (GN) by performing the
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union of all nodes and edges of KEGG human signaling pathways. In a number of KEGG
pathways, a gene ’a’ interacts with gene ’b’, through an intermediate pathway ’A’. This is
represented by a link that starts from gene ’a’ to gene ’b’ through pathway ’A’. For example,
in the Adherence Junction pathway, TGFβR activates Smad3 through the TGF-beta signaling pathway. Interactions between genes belonging to the pathway ’A’ and genes ’a’ and
’b’ are not included in our model. There are some interactions between genes/pathways
through DNA or small molecules in KEGG. For instance, there is a link between MAPK
signaling pathway and Phosphatidylinositol signaling system through a small molecule
(compound) IP3 in KEGG. Such interactions are not part of the scope of this analysis and
we do not include them in constructing the global network [205]. We used ROntoTools
package [276] (version 1.2.0) to calculate the union all KEGG signaling pathways that
are represented by the adjacency matrices and obtain a unified adjacency matrix. In this
step, we included some implicit interactions between the genes by performing the union
of adjacency matrices representing KEGG signaling pathways. For example, suppose gene
’a’ activate gene ’b’ in pathway ’A’ and gene ’b’ activates gene ’c’ in pathway ’B’. A path
between gene ’a’ and gene ’c’ may be constructed by our analysis, while there was no path
between them before this analysis.
Next, given the two sets of disease-related genes as Diseaset = {x1 , x2 , ..., xn }, and
drug targets as Drugt = {y1 , y2 , ..., yn }, we extract a subgraph of GN that consists of all
the shortest paths connecting genes belonging to these sets. It means that a gene from
either Diseaset or Drugt can be a source or destination of the shortest path extracted
from GN. This subgraph called Drug-disease network (DDN) represents all the interactions
between drug targets and genes related to the given disease, through all the interactions
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Figure 1: Framework overview. A) We construct a global network (GN) that is the union of
all KEGG human signaling pathways. For each drug-disease pair, we extract a subgraph of
GN, namely DDN, consisting of all shortest paths between two sets of disease-related genes
and drug targets. B) We then generate gene perturbation signatures of drug-disease pairs
by applying a system-level analysis on their gene expression signatures in the drug-disease
network (DDN). A comparative analysis is applied on drug and disease gene perturbation
signatures. A repurposing score is assigned to each drug-disease pair. Finally, a ranked
list of drugs with potential therapeutic effects for the given disease is generated based on
repurposing scores.
described in KEGG signaling pathways.
2.4.2

Drug-disease repurposing score computation

In this stage, we capture the impact caused by a drug exposure or a disease on the genes
that are specific to the condition of interest. In order to integrate the drug and disease
gene expressions signatures, we generate gene perturbation signatures by computing the
amount of perturbation upon the genes belonging to the drug-disease network (DDN)
for all drug-disease pairs, as shown in Figure 1B. The gene perturbation signatures are
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calculated using the impact analysis method [71] on the subgraph of global network we
constructed in previous step. The impact analysis (IA) takes into account the structure and
dynamics of a signaling pathway by considering a number of important aspects, including
the measured gene expression changes, the direction and type of every gene signal, and
the position and role of every gene in a pathway. A perturbation factor for each gene,
P F (gi ), is calculated using the impact analysis method [71], as follows:
A perturbation factor for each gene, P F (gi ), is calculated using the impact analysis
method [71], as follows:

P F (gi ) = ∆E(gi ) +

n
X
j=1

βij

P F (gj )
Nds (gj )

(2.1)

where the term ∆E(gi ) denotes the signed normalized measured expression change of
a gene gi , added to the sum of all perturbation factors of the genes gj that are direct upstream of the gene gi , normalized by the number of downstream genes of gj , Nds (gj ). The
coefficient βij represents the type of the interaction, βij = 1 for activation and induction,
and βij = −1 for inhibition and repression. The second term in Equation (2.1) involves the
PF values of those genes that are upstream of the gene for which the perturbation factor
is calculated. For a gene with no upstream genes, the PF will be the measured expression
gene ∆E(g).
Next, we calculate the repurposing scores for drug-disease pairs by computing the Pearson correlation coefficient between their gene perturbation signatures. The result score is
from -1 to 1, where a high positive score shows that the drug and the disease both cause
similar perturbations in the system, and therefore, that drug may cause the same effect
as the disease. Conversely, a high negative score shows that the drug and disease have
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opposite gene perturbation signatures. Our hypothesis is that if the perturbation caused
by a particular drug in the system is the reverse of the perturbation caused by a disease,
that drug may have the potential to treat the given disease. Thus, we rank drugs from the
strongly anti-correlated to the strongly correlated, according to their repurposing pathway
perturbation scores.
In order to estimate the statistical significance of drug candidate repurposing scores, we
generate 1,000 random drug gene expression signatures (by permuting gene labels), and
then calculate random repurposing scores for all drug-disease pairs. We compute p-values
as the percentage of the random scores higher than the observed score.
2.4.3

A systematic method to select repurposing candidates

We used a systematic method in order to rank repurposing candidates. To do this, given
a ranked-list of drugs (drug instances) obtained by applying our approach on a disease
dataset, we first compute a score for each drug that indicates how better or worse that
drug is ranked in comparison to already FDA-approved drugs as follows:

score(Drugx ) = a − b

(2.2)

where a denotes the number of already FDA-approved drugs (gold standards) that are
ranked worse than Drugx , and b denotes the number of FDA-approved drugs that are
ranked better than Drugx (see Figure 3). For instance, if there were N FDA-approved
drugs for a condition and an instance of a repurposing candidate were ranked higher than
all N FDA approved drugs, the score of this candidate would be N . Conversely, if the
candidate were ranked lower than all N FDA approved drugs, its score would be −N .
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Figure 2: A systematic method [205] to select repurposing drug candidates. A) Given
a set of ranked lists of drugs (drug instances), we compute a score for each drug. B)
We then calculate an average score for each drug instance across different lists (using
disease datasets). C) Finally, we calculate an average score for each distinct drug across
the instances, in case there are multiple instances for that drug.
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Figure 3: Drug repurposing score computation. A) Given a ranked-list of drugs (drug instances) obtained by applying our approach on a disease dataset, a score is assigned to
each drug indicating how better or worse that drug is ranked in comparison to already
FDA-approved drugs. The score for Drugx is defined as Score(Drugx ) = a − b, where a
and b denote the number of already FDA-approved drugs that are ranked worse and better than Drugx , respectively. B) The non-small cell lung cancer (NSCLC): in total there
are 8 drugs that are already FDA-approved for treatment of NSCLC. Table I shows the
lists of 10 top-ranked drugs, results of the proposed approach using 4 NSCLC datasets:
GSE11969-adenocarcinoma, GSE11969-large cell carcinoma, GSE11969-squamous cell
carcinoma, and GSE32863-adenocarcinoma. The scores for GSM1741743_sirolimus,
GSM1738326_mocetinostat, and GSM1740080_sunitinib across NSCLC datasets are summarized in Table II. A score of 8 means that each candidate ranked higher than all 8
instances of FDA-approved drugs.
Using this objective measure, we then calculate an average score for each drug across
different disease datasets (Figure 2B ). And finally, we compute an average score for each
distinct drug across different instances, if there are multiple instances for that drug (Figure 2C). We select the top 5% drug candidates from the ranked lists obtained by applying
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our approach on disease datasets and rank such drugs based on the scores computed by
the this method, from highest to the lowest.
2.5

Discussion and results
To validate our approach, we analyzed 19 datasets from four different conditions: id-

iopathic pulmonary fibrosis (IPF) (6 datasets), non-small cell lung cancer (NSCLC) (4
datasets), prostate cancer (3 datasets), and breast cancer (6 datasets).
We compare the results of 3 computational drug repurposing approaches: our systemlevel approach, the most popular approach proposed by [248] (henceforth drug-disease),
and a classical method based on disease and drug signature anti-correlation (henceforth
anti-correlation).
Both the drug-disease and the anti-correlation approaches are based on the hypothesis
that if gene expression signature is perturbed in one direction in a disease state, and in
the opposite (reverse) direction upon a drug exposure, then that drug may have the potential therapeutic effect for the disease. The difference between the two approaches is
related on the approach used to calculated the match between a disease and a drug. Given
a disease gene expression signature (query signature) and a drug gene expression signatures (reference signature), the Sirota et al.’s drug-disease similarity approach calculate an
enrichment score for the up-regulated and down-regulated disease genes (by applying a
Kolmogorov-Smirnov (KS) test). We use the R implementation of this approach available
in the package DrugVsDisease [197].
In contrast, the classical anti-correlation method calculates a similarity score for drugdisease pairs by computing the Pearson correlation coefficient between the drug gene expression signature and the given disease gene expression signature. Drugs are ranked from
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Table 2: Preliminary support by preclinical or clinical studies showing the therapeutic
potential of the proposed candidates. These candidates are currently FDA-approved but
for other indications.
Disease
IPF

Proposed candidate
Sunitinib
Dabrafenib
Nilotinib
NSCLC
Sunitinib
Sirolimus
Everolimus
Ponatinib
Prostate cancer Podophyllotoxin
Acetylsalicylic acid
Papaverine
Mefloquine
Vorinostat
Sirolimus
Breast cancer
Captopril
Glibenclimiade
Fluorometholone
Etoposide
Colchicine
Tretinoin

Preclinical / clinical evidence
[92, 143, 222]
[163, 193, 301]
[1, 8, 15, 38, 46, 91, 104, 220]
[189, 251]
[30, 77, 90, 234]
[90, 212, 252]
[44, 45, 81, 84, 218, 263]
[25, 48, 53, 88, 109, 137, 159]
[29, 52, 97, 118, 160, 188, 229, 249]
[89, 112, 236]
[85, 247, 294]
[32, 39, 66, 130]
[9, 40, 114, 215]
[123, 129, 144, 185, 225, 230]
[2, 190, 202, 213, 224, 299]
[127, 132, 155]
[18, 305, 306]
[255]
[33, 82, 157, 199, 256]

ClinicalTrials.gov ID

NCT00092001, NCT00372775, NCT00693992, NCT00864721
NCT00923273
NCT01061788
NCT01813734
NCT02757365,NCT03103152,NCT02804815
NCT00330161,NCT00589472
NCT00311623,NCT02565901
NCT00086723
NCT00026949, NCT01492556, NCT01589159

the highly anti-correlated to the highly correlated, according to their score.
The Anatomical Therapeutic Chemical ATC drug classification system, recommended
by the World Health Organization (WHO) (http://www.whocc.no/atc/) provides a useful
classification information based on drugs mechanism of actions. However, it is not precise
enough to be considered as the gold standard. Drugs from the same class may not have
the exact therapeutic desired effect for a condition. For instance, Nintedanib is an antineoplastic agent in L01 ATC class and it is the FDA-approved drug for treatment of IPF.
However, not all drugs in the antineoplastic class have promising therapeutic effects on
IPF because of pulmonary toxicities [69]. Hence, using the ATC class to repurpose drugs
or even validate drug repurposing results is not feasible.
In this study, we compare the various approaches based on their ability to identify drugs
that have already been FDA-approved for that condition (gold standard), based exclusively
on the molecular data. In essence, a good repurposing approach should place already
approved drugs at the very top of the list of drugs proposed for that particular disease. We
used the Wilcoxon rank sum test [285] to determine whether the proposed approach is
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significantly better than the existing approaches.
Table 2 shows the proposed candidates for treatment of four human diseases: IPF,
NSCLC, prostate cancer, breast cancer, and preliminary evidences that support the usefulness of those candidates in treatment of the given diseases.
2.5.1

Idiopathic pulmonary fibrosis

The list of IPF datasets we used in our analysis is summarized in Table 3. We compare
the results of our approach with the existing approach proposed by [248] (drug-disease),
as well as the classical method (anti-correlation). The lists of the top 10 drugs are summarized in Table 4.
Table 3: Idiopathic pulmonary fibrosis (IPF) datasets
Dataset
GSE1724
GSE21369
GSE24206-advanced
GSE24206-early
GSE44723
LGRC

Source
NCBI GEO [219]
NCBI GEO [51]
NCBI GEO [176]
NCBI GEO [176]
NCBI GEO [204]
Lung Genomics Research Consortium

Samples
Treated (TGFbeta) vs untreated
Interstitial lung disease vs healthy
Advance stage IPF vs healthy
Early stage IPF vs healthy
Rapid progressing IPF vs healthy
Interstitial lung disease vs healthy

Gold standard:Nintedanib is the only FDA-approved drug for IPF in our drug input
datasets (highlighted as green). It inhibits RTKs such as PDGFR (α , β), FGFR(1,2,3),
VEGFR(1,2,3), and FLT3, among them, FGFR, PDGFR, and VEGFR have been implicated in
the pathogenesis of IPF. Additionally, Nintedanib inhibits nRTKs such as Lck, Lyn and Src
kinases [91, 103, 131, 171, 214, 254, 289].
We select the top 5% of drugs ranked lists obtained by applying the proposed approach
on 6 IPF datasets. As shown in Table 5, these drugs are ranked from the highest to the
lowest, based on their scores. The score assigned to Nintedanib is 0. Since we have four
instances for Nintedanib, drugs scores range between -4 and 4. The largest negative score

Proposed
Drug-disease
GSE24206-early
GSM1740570_saracatinib
GSM1746916_radicicol
GSM1743214_nintedanib
GSM1746864_radicicol
GSM1742836_celastrol
GSM1738326_mocetinostat*
GSM1745714_buparlisib
GSM1738291_azacitidine*
GSM1742552_linifanib
GSM1738794_garcinol*
GSM1742850_nintedanib
GSM1745213_nilotinib*
GSM1740917_saracatinib
GSM1737397_quizartinib*
GSM1740731_CH5424802 GSM1743996_sirolimus*
GSM1743268_linifanib
GSM1742836_celastrol
GSM1739549_saracatinib
GSM1746893_radicicol
GSE44723
GSM1741104_sunitinib*
GSM1737411_NVP-BGT226
GSM1740080_sunitinib*
GSM1743823_fostamatinib*
GSM1742552_linifanib
GSM1745509_NVP-BEZ235
GSM1744393_gefitinib*
GSM1737409_NVP-BGT226
GSM1737353_everolimus* GSM1738100_tranylcypromine*
GSM1742436_GDC-0941
GSM1741779_vorinostat*
GSM1743268_linifanib
GSM1742856_canertinib*
GSM1743214_nintedanib
GSM1742795_palbociclib*
GSM1741743_sirolimus*
GSM1739241_olaparib*
GSM1740570_saracatinib
GSM1740387_CH5424802
LGRC-ILD
GSM1740570_saracatinib
GSM1738326_mocetinostat*
GSM1739549_saracatinib
GSM1742795_palbociclib*
GSM1740917_saracatinib
GSM1737410_NVP-BGT226
GSM1743214_nintedanib
GSM1741779_vorinostat*
GSM1743268_linifanib
GSM1737624_entinostat
GSM1742552_linifanib
GSM1737411_NVP-BGT226
GSM1742504_nintedanib
GSM1739435_belinostat*
GSM1744170_GDC-0941
GSM1737409_NVP-BGT226
GSM1745714_buparlisib
GSM1737455_vandetanib*
GSM1741265_saracatinib
GSM1738350_pracinostat

Proposed
GSE24206-advanced
GSM1746916_radicicol
GSM1740570_saracatinib
GSM1746864_radicicol
GSM1743214_nintedanib
GSM1746893_radicicol
GSM1745714_buparlisib
GSM1742836_celastrol
GSM1742836_celastrol
GSM1738290_azacitidine*
GSM1742552_linifanib
GSM1738291_azacitidine*
GSM1740917_saracatinib
GSM1745530_nilotinib*
GSM1739549_saracatinib
GSM1745213_nilotinib*
GSM1742850_nintedanib
GSM1742552_linifanib
GSM1740731_CH5424802
GSM1742716_sorafenib*
GSM1745213_nilotinib*
GSE21369
GSM1737409_NVP-BGT226 GSM1737700_rucaparib*
GSM1737411_NVP-BGT226 GSM1740570_saracatinib
GSM1740923_BI-2536*
GSM1745714_buparlisib
GSM1740576_BI-2536*
GSM1740731_CH5424802
GSM1745509_NVP-BEZ235
GSM1745213_nilotinib*
GSM1740570_saracatinib
GSM1742504_nintedanib
GSM1737412_NVP-BGT226 GSM1737448_idelalisib*
GSM1737353_everolimus*
GSM1745530_nilotinib*
GSM1745194_NVP-BEZ235
GSM1742836_celastrol
GSM1738308_entinostat
GSM1739679_dabrafenib*
GSE1724
GSM1738326_mocetinostat* GSM1741104_sunitinib*
GSM1737624_entinostat
GSM1740570_saracatinib
GSM1739358_mocetinostat* GSM1739549_saracatinib
GSM1739435_belinostat*
GSM1742552_linifanib
GSM1741779_vorinostat*
GSM1745714_buparlisib
GSM1737410_NVP-BGT226 GSM1743268_linifanib
GSM1746864_radicicol
GSM1740917_saracatinib
GSM1741767_vorinostat*
GSM1740080_sunitinib*
GSM1737409_NVP-BGT226 GSM1742706_alvocidib
GSM1737642_mocetinostat* GSM1742850_nintedanib

Anti-correlation

Anti-correlation
GSM1746916_radicicol
GSM1746864_radicicol
GSM1746893_radicicol
GSM1738290_azacitidine*
GSM1742836_celastrol
GSM1738291_azacitidine*
GSM1742552_linifanib
GSM1743996_sirolimus*
GSM1742716_sorafenib*
GSM1745530_nilotinib*
GSM1737700_rucaparib*
GSM1737699_rucaparib*
GSM1738767_decitabine*
GSM1740731_CH5424802
GSM1737385_motesanib*
GSM1737624_entinostat
GSM1744048_imatinib*
GSM1737698_rucaparib*
GSM1738290_azacitidine*
GSM1741754_sirolimus*
GSM1746916_radicicol
GSM1742552_linifanib
GSM1742836_celastrol
GSM1745213_nilotinib*
GSM1743268_linifanib
GSM1746864_radicicol
GSM1745626_vemurafenib
GSM1743197_celastrol
GSM1744371_selumetinib
GSM1746881_mitoxantrone*

Drug-disease
GSM1746916_radicicol
GSM1746864_radicicol
GSM1738291_azacitidine*
GSM1746893_radicicol
GSM1738772_ischemin
GSM1742836_celastrol
GSM1737397_quizartinib*
GSM1738326_mocetinostat*
GSM1742718_sorafenib*
GSM1746811_ruxolitinib*
GSM1737352_everolimus*
GSM1737699_rucaparib*
GSM1737700_rucaparib*
GSM1738767_decitabine*
GSM1746916_radicicol
GSM1737385_motesanib*
GSM1742800_palbociclib*
GSM1737990_mocetinostat*
GSM1737443_idelalisib*
GSM1742836_celastrol
GSM1746800_nilotinib*
GSM1746916_radicicol
GSM1743953_linifanib
GSM1742836_celastrol
GSM1745958_dasatinib*
GSM1743268_linifanib
GSM1741215_veliparib*
GSM1741184_regorafenib*
GSM1747067_mitoxantrone*
GSM1741566_veliparib*

Table 4: A comparison between the results of three approaches: proposed, drug-disease, anti-correlation using IPF datasets
(the top 10 drugs). The p-values for Wilcoxon rank sum test comparing the results of the proposed approach and drug-disease
approach using datasets GSE24206-early, GSE24206-advanced, GSE44723, GSE21369, LGRC- ILD, GSE1724 datasets are
0.02, 0.02, 0.01, 0.02, 0.01, 0.01, respectively. Using these datasets. The p-values for Wilcoxon rank sum test comparing
the results of the proposed approach and Anti-correlation approach using are 0.02, 0.02, 0.01, 0.02, 0.01, 0.01, respectively.
Drugs highlighted with green are FDA-approved for the treatment of IPF. The * denotes the drugs that are currently FDAapproved but for other indications. The proposed approach was the only one that was able to rank the FDA-approved
Nintedanib in the top 10. In contrast, none of the existing approaches was able to retrieve the FDA-approved drug in any of
these 6 datasets.
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Table 5: The top 5% drugs obtained from the result of our repurposing approach. These
drugs are ranked based on the scores generated by the systematic method. The * denotes the drugs that are currently FDA-approved but for other indications. The score for
Nintedanib, the FDA-approved drug for IPF, is 0. Drugs with the same scores are sorted
based on their average ranks. In this analysis, the scores computed by our systematic
method can be further normalized based on dividing each score by the total number of
FDA-approved drug instances for the disease of interest (e.g. 4 FDA-approved drug instances for IPF). Therefore, the scores calculated for each drug across different diseases
will be in the same range (-1,1). For instance, the normalized score for Saracatinib will be
0.37.
Drug
Score
Saracatinib
1.5
Nintedanib
0
Linifanib
-0.67
Sunitinib *
-1.42
Buparlisib
-1.83
GDC-0941
-1.92
Alvocidib
-2.58
Dabrafenib * -2.67
Nilotinib *
-2.83
Gefitinib *
-2.92
Idelalisib *
-2.92
CH5424802 -3
Everolimus * -3
Dovitinib
-3
Rucaparib * -3.08
Celastrol
-3.08
NVP-BEZ235 -3.17
Selumetinib -3.17
Erlotinib *
-3.58
Sirolimus *
-3.58
for a drug indicates that drug ranked worse than all four instances of Nintedanib. Drugs
with the same scores are sorted based on their average ranks in drugs ranked lists.
In this analysis, the scores computed by our systematic method can be further normalized based on dividing each score by the total number of FDA-approved drug instances for
the disease of interest (e.g. 4 FDA-approved drug instances for IPF). Therefore, the scores
calculated for each drug across different diseases will be in the same range (-1,1). For
instance, the normalized score for Saracatinib will be 0.37.
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Proposed candidates: We propose Sunitinib (p = 0.0009), Dabrafenib (p = 0.0009),
and Nilotinib (p = 0.0009) as repurposing candidates for treatment of IPF. Saracatinib,
Linifanib, Buparlisib, GDC-0941, and Alvocidib are also highly ranked by our approach
for treatment of IPF. Although these drugs are not approved by FDA yet, they can be
considered for further experimental tests.
Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), including vascular endothelial growth factor receptors (VEGFR) and platelet-derived growth
factor receptors (PDGFR). It is approved by FDA for the treatment of Gastrointestinal
stromal tumor, advanced renal cell carcinoma, and progressive well-differentiated pancreatic neuroendocrine tumors [64, 183]. It was investigated for its anti-fibrotic and antiangiogenic properties. Its efficiency was experimentally proved in a bleomycin-induced
mouse model and it has been proposed for the treatment of IPF [143]. Results of in vitro
studies and animal models show that receptor tyrosine kinases, such as PDGFR, VEGFR and
FGFR, and non-receptor tyrosine kinases, such as the Src family, play crucial roles in the
pathogenesis of IPF [92, 222].
Dabrafenib is approved by FDA for the treatment of patients with unresectable or
metastatic melanoma. Recent clinical studies demonstrate that the extracellular signal
regulated kinase (ERK) and mitogen-activated protein kinase (MAPK) are up-regulated in
lung tissues of patients with IPF [163, 301]. In particular, results of studies on MAPK
signaling pathways show that the level of serine/threonine-protein kinase B-Raf (BRAF)
is increased in patients samples compared to the normal ones, suggesting the potential
therapeutic effects of MEK/ERK inhibitors for pulmonary fibrosis [163, 193]. This supports
the idea that the BRAF inhibitor Dabrafenib may have atherapeutic effect on IPF.
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Nilotinib is another FDA-approved drug we propose to be repurposed for the treatment
of IPF. Nilotinib is a transduction inhibitor targeting BCR-ABL, c-kit, and PDGF, that is
approved by FDA for treatment of patients who are newly diagnosed with Philadelphia
chromosome positive chronic myeloid leukemia (Ph+CML). It is also used for treatment
of patients with Ph+CML in chronic phase and accelerated phase if they were resistant (or
intolerant) to previous treatments. The potential roles of PDGFs in IPF have been shown
by many studies [8, 15, 38, 104, 289]. The advantage of PDGF inhibition in IPF is well
studied and supported by several studies [1, 46, 281, 289]. Authors of [91, 220] confirmed
the potential effect of Nilotinib in decreasing the extent of pulmonary fibrosis in a mouse
model.
The phosphatidylinositol 3 kinase (PI3K) inhibitors Buparlisib and GDC-0941 are undergoing clinical trials for a number of diseases. Buparlisib is in Phase III of clinical
trials for treatment of breast cancer and in and Phase II for several other solid tumors.
GDC-0941(Pictilisib) has been used in clinical trials for the treatment of several cancers,
including breast cancer. Preclinical studies proved that PI3K inhibitors have potential
roles in treatment of IPF by interfering with the fibrogenic effects of T GF − β1 signaling [26, 59, 107, 178]. Based on this evidence, Buparlisib and GDC-0941 may have potential therapeutic effects on IPF.
The tyrosine kinase inhibitors Saracatinib and Linifanib are also highly ranked by
our approach for treatment of IPF. Saracatinib (AZD0530) is an oral, tyrosine kinase inhibitor selective for Src. It underwent clinical tests at AstraZeneca for the treatment of
cancer [94, 148, 179, 211]. However, it failed to show a sufficient efficacy in these studies. Subsequently, it was proposed for other usages such as Alzheimer’s disease (in Phase
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II) [191]. Linifanib (ABT-869) is also a multi-targeted receptor tyrosine kinase inhibitor
that is intended to suppress tumor growth. It is investigated for treatment of leukemia
(myeloid), myelodysplastic syndrome, and solid tumors [47, 50, 279]. The efficiency and
tolerability of Linifanib versus Sorafenib has been assessed in patients with advanced hepatocellular carcinoma [36]. The tyrosine kinase inhibitors are proven to be effective in
treatment of IPF [4, 6, 26, 91, 152, 222, 288]. In particular, the Src kinase inhibitor Saracatinib is reported to be useful in treatment of IPF through targeting the T GF −β signaling
pathway [108].
The Food and Drug Administration’s Office of Orphan Products Development provides
orphan drug status to medicines that are designed for the treatment, diagnosis or prevention of rare conditions or diseases that affect fewer than 200,000 people in the U.S
or that affect more than 200,000 people but are not expected to recover the costs of
developing and marketing a treatment drug [246, 273]. IPF has a significant affect on
patients’ lives and finding optimal treatments for this condition is extremely important
(https://pulmonaryfibrosisnews.com). More specifically, Saracatinib is currently in (STOP
IPF) trial for the treatment of patients with IPF where 100 participants with IPF will receive
either Saracatinib or placebo for 24 weeks [6]. In this trial, the safety and tolerability of
Saracatinib as well as the early indicators of Saracatinib efficacy and the relevant biomarkers of Src kinase activity and fibrogenesis in treatment of IPF will be evaluated [6].
Alvocidib is a cyclin-dependent kinase (CDK) inhibitor that is undergoing clinical trials for a number of cancers: esophageal cancer, leukemia, lung cancer, liver cancer, and
lymphoma. Studies of murine models show that the CDK inhibitors block the epithelial
apoptosis and decrease the tissue fibrosis in pulmonary fibrosis [115, 150]. As a result,
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CDK inhibitors have been suggested as a novel therapeutic strategy against IPF [310].
Drug-disease networks

Figure 4: The chord diagram represents the subnetwork of DDN for Nintedanib, the FDAapproved drug for IPF. In order to obtain this subnetwork, we used IPF-associated genes
that are included in KEGG’s Pathways in cancer (the target pathway for Nintedanib). Sectors and chords represent the genes and associations between the genes in the network,
respectively. Red sectors represent genes known to be associated to IPF disease. Sectors
representing the Nintedanib target genes are green.

We used chord diagrams to represent subnetworks of drug-disease networks (DDN) for
Nintedanib (Figure 4), Sunitinib (Figure 5), Linifanib (Figure 6), and Saracatinib (Figure 7). In order to obtain the subnetworks we use IPF-associated genes belonging to the
Pathways in cancer, the target pathway for Nintedanib. The subnetwork S= (V,E) with the
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node set V and edge set E is represented as follow:

S = (V, E) : (V ⊂ P ath ∩ (Diseaset ∪ Drugt )) ∧ (E ⊂ DDN )

(2.3)

where Diseaset = {x1 , x2 , ..., xn }, Drugt = {y1 , y2 , ..., yn }, and P ath denote the diseaserelated genes, drug targets, and the genes on the Pathways in cancer, respectively.
In the chord diagram, sectors represent the genes and the chords represent the associations between various genes in the network we built. The red sectors represent the
genes known to be associated to IPF. The green sectors represent the genes targeted by
Nintedanib.
In addition to chord diagrams, we used the edge lists to represent the DDN subnetworks
we construct for the repurposing candidates. In this list, the association between the genes
is represented as a tuple (e.g. FGFR1 - KRAS). Table 6 shows the edge lists representing
DDN subnetworks for repurposing drugs: Nintedanib, Nilotinib, and Sunitinib.
Table 7 shows the edge lists representing DDN subnetworks for drugs: Linifanib and
Saracatinib. These drugs are currently undergoing clinical trials for several indications
(see detail in section 3.1 of the manuscript). Red entires represent genes known to be
associated to IPF disease. Entries representing the Nintedanib target genes are green.
Drug-drug networks
Figures 9 and 8 show the drug-drug networks we generated using the known knowledge (target pathways and target genes) of Nintedanib (FDA-approved for IPF treatment)
and top-ranked candidates for IPF, where circles correspond to drugs, and two drugs being
connected if they share target pathways or target genes, respectively. The target path-
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Table 6: The edge lists represent the subnetwork of DDN of drugs: Nintedanib, Nilotinib,
and Sunitinib. Nintedanib is the FDA-approved drug for IPF treatment. Nilotinib and Sunitinib are the repurposing candidates for the treatment of IPF. In this list, the association
between two genes is represented as gene pairs. In order to obtain the subnetworks, we
used IPF-associated genes that are included in KEGG’s Pathways in cancer (the target pathway for Nintedanib). Red entires represent genes known to be associated to IPF disease.
Entries representing the Nintedanib target genes are green.
Nintedanib

Nilotinib

Sunitinib

Gene1 → Gene2

Gene1 → Gene2

Gene1 → Gene2

Gene1 → Gene2

Gene1 → Gene2

Gene1 → Gene2

FGFR1
FGFR1
FGFR1
PDGFRα
PDGFRβ
FGF2
FGF2
FGF2
FGF2
FGF2
HGF
HGF
HGF
HGF
HGF
VEGFA
VEGFA
VEGFA
VEGFA
VEGFA
AKT1
AKT1
AKT1
BAX
BAX
BIRC5
CASP9
CYCS
CYCS
FOS
FOS
JUN
JUN
JUN
JUN
KRAS

JUN
KRAS
KRAS
MAPK1
MAPK1
MAPK1
MAPK1
MAPK1
MAPK1
MAPK1
MAPK3
MAPK3
MAPK3
MAPK3
MAPK3
MAPK3
MAPK3
MYC
MYC
MYC
NFKB1
NFKB1
NFKB1
NFKB1
NFKB1
NFKB1
NFKB1
RELA
RELA
RELA
RELA
RELA
RELA
RELA
TGFB1
TRAF2

PDGFRα
PDGFRβ
FGF2
FGF2
HGF
HGF
VEGFA
VEGFA
AKT1
AKT1
AKT1
BAX
BAX
BIRC5
CASP9
CYCS
FOS
JUN
KRAS
KRAS
MAPK1
MAPK1
MAPK1
MAPK1
MAPK1
MAPK1
MAPK1
MAPK3
MAPK3
MAPK3
MAPK3
MAPK3
MAPK3
MAPK3
MYC
MYC

MYC
NFKB1
NFKB1
NFKB1
NFKB1
NFKB1
NFKB1
NFKB1
RELA
RELA
RELA
RELA
RELA
RELA
RELA
TGFB1

FGFR1
FGFR1
FGFR1
PDGFRα
PDGFRβ
FGF2
FGF2
HGF
HGF
HGF
HGF
VEGFA
VEGFA
VEGFA
VEGFA
VEGFA
FGF2
FGF2
AKT1
AKT1
AKT1
AKT1
BAX
BAX
BIRC5
CASP9
CYCS
FOS
FOS
FOS
FOS
JUN
JUN
JUN
JUN
JUN

JUN
KRAS
KRAS
MAPK1
MAPK1
MAPK1
MAPK1
MAPK1
MAPK1
MAPK1
MAPK3
MAPK3
MAPK3
MAPK3
MAPK3
MAPK3
MAPK3
MYC
MYC
MYC
NFKB1
NFKB1
NFKB1
NFKB1
NFKB1
NFKB1
NFKB1
RELA
RELA
RELA
RELA
RELA
RELA
RELA
SMAD3
TGFB1
TP53
TRAF2
TRAF2

KRAS
MAPK1
MAPK3
KRAS
KRAS
FGFR1
FGFR2
FGFR3
PDGFRα
PDGFRβ
FGFR1
FGFR2
FGFR3
PDGFRα
PDGFRβ
FGFR1
FGFR2
FGFR3
PDGFRα
PDGFRβ
NFKB1
NFKBIA
RELA
CASP9
CYCS
CASP9
CASP3
CASP3
CASP9
MMP2
VEGFA
MMP2
NFKB1
RELA
VEGFA
MAPK1

VEGFA
MAPK1
MAPK3
CDKN1A
IL6
MMP9
MYC
NFKB1
RELA
TP53
CDKN1A
IL6
MMP9
MYC
NFKB1
RELA
TP53
MMP2
MMP9
VEGFA
BCL2
BIRC2
IL6
MMP9
NFKBIA
TRAF2
VEGFA
BCL2
BIRC2
IL6
MMP9
NFKBIA
TRAF2
VEGFA
SMAD3
BIRC2

KRAS
KRAS
PDGFRα
PDGFRβ
PDGFRα
PDGFRβ
PDGFRα
PDGFRβ
NFKB1
NFKBIA
RELA
CASP9
CYCS
CASP9
CASP3
CASP3
VEGFA
VEGFA
MAPK1
MAPK3
CDKN1A
IL6
MMP9
MYC
NFKB1
RELA
TP53
CDKN1A
IL6
MMP9
MYC
NFKB1
RELA
TP53
MMP2
MMP9

VEGFA
BCL2
BIRC2
IL6
MMP9
NFKBIA
TRAF2
VEGFA
BCL2
BIRC2
IL6
MMP9
NFKBIA
TRAF2
VEGFA
SMAD3

KRAS
MAPK1
MAPK3
KRAS
KRAS
PDGFRα
PDGFRβ
FGFR1
FGFR2
PDGFRα
PDGFRβ
FGFR1
FGFR2
FGFR3
PDGFRα
PDGFRβ
FGFR1
FGFR2
BCL2
NFKB1
NFKBIA
RELA
CASP9
CYCS
CASP9
CASP3
CASP3
IL6
MMP2
MMP9
VEGFA
IL6
MMP2
MMP9
NFKB1
RELA

VEGFA
MAPK1
MAPK3
CDKN1A
IL6
MMP9
MYC
NFKB1
RELA
TP53
CDKN1A
IL6
MMP9
MYC
NFKB1
RELA
TP53
MMP2
MMP9
VEGFA
BCL2
BIRC2
IL6
MMP9
NFKBIA
TRAF2
VEGFA
BCL2
BIRC2
IL6
MMP9
NFKBIA
TRAF2
VEGFA
CDKN1A
SMAD3
CDKN1A
BIRC2
NFKBIA
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Table 7: The edge lists represent the subnetwork of DDN of drugs: Linifanib and Saracatinib. These drugs are currently undergoing clinical trials (for conditions other than IPF)
that can be considered for the treatment of IPF. In this list, the association between two
genes is represented as a tuple. In order to obtain the subnetworks, we used IPF-associated
genes that are included in KEGG’s Pathways in cancer (the target pathway for Nintedanib).
Red entires represent genes known to be associated to IPF disease. Entries representing
the Nintedanib target genes are green.
Linifanib

Saracatinib

Gene1 → Gene2
PDGFRβ KRAS
FGF2
PDGFRβ
HGF
PDGFRβ
VEGFA
PDGFRβ
AKT1
NFKB1
AKT1
NFKBIA
AKT1
RELA
BAX
CASP9
BAX
CYCS
BIRC5
CASP9
CASP9
CASP3
CYCS
CASP3
JUN
VEGFA
KRAS
MAPK1
KRAS
MAPK3
MAPK1
CDKN1A
MAPK1
IL6
MAPK1
MMP9
MAPK1
MYC
MAPK1
NFKB1
MAPK1
RELA
MAPK1
TP53
MAPK3
CDKN1A
MAPK3
IL6
MAPK3
MMP9
MAPK3
MYC
MAPK3
NFKB1
MAPK3
RELA
MAPK3
TP53
MYC
MMP2
MYC
MMP9
MYC
VEGFA
NFKB1
BCL2
NFKB1
BIRC2
NFKB1
NFKBIA
NFKB1
TRAF2
NFKB1
VEGFA
RELA
BCL2
RELA
BIRC2
RELA
NFKBIA
RELA
TRAF2
RELA
VEGFA
TGFB1
SMAD3

Gene1 → Gene2
FGFR1
MAPK1
FGFR1
MAPK3
PDGFRα KRAS
FGF2
PDGFRα
FGF2
PDGFRβ
HGF
PDGFRα
HGF
PDGFRβ
VEGFA
FGFR1
AKT1
NFKB1
AKT1
NFKBIA
AKT1
RELA
BAX
CASP9
BAX
CYCS
BIRC5
CASP9
CASP9
CASP3
CYCS
CASP3
FGF2
FGFR1
FOS
IL6
FOS
VEGFA
HGF
FGFR1
JUN
NFKB1
JUN
RELA
JUN
VEGFA
KRAS
MAPK1
KRAS
MAPK3
MAPK1
CDKN1A
MAPK1
IL6
MAPK1
MMP9
MAPK1
MYC
MAPK1
NFKB1
MAPK1
RELA
MAPK1
TP53
MAPK3
CDKN1A
MAPK3
IL6
MAPK3
MMP9
MAPK3
MYC
MAPK3
RELA
MAPK3
TP53
MYC
MMP2
MYC
MMP9
MYC
VEGFA
NFKB1
BCL2
NFKB1
BIRC2

Gene1 → Gene2
NFKB1 BIRC2
NFKB1 IL6
NFKB1 MMP9
NFKB1 NFKBIA
NFKB1 TRAF2
NFKB1 VEGFA
RELA
BCL2
RELA
BIRC2
RELA
IL6
RELA
MMP9
RELA
NFKBIA
RELA
TRAF2
RELA
VEGFA
TGFB1 SMAD3
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Figure 5: The chord diagram represents the subnetwork of DDN for Sunitinib, the repurposing candidate for the treatment of IPF. In order to obtain this subnetwork, we used
IPF-associated genes that are included in KEGG’s Pathways in cancer (the target pathway
for Nintedanib). Sectors and chords represent the genes and associations between the
genes in the network, respectively. Red sectors represent genes known to be associated to
IPF disease. Sectors representing the Nintedanib target genes are green.
ways and target genes of drugs (represented by rectangles) are obtained from KEGG and
Drugbank [287].
2.5.2

Non-small cell lung cancer

We obtained four non-small cell lung cancer (NSCLC) datasets from Gene Expression
Omnibus (GEO): GSE32863 (adenocarcinoma) [241] and GSE11969 (subtypes: adenocarcinoma, large cell carcinoma, squamous cell carcinoma) [258]. Adenocarcinoma (40%
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Figure 6: The chord diagram represents the subnetwork of DDN for Linifanib. In order to
obtain this subnetwork, we used IPF-associated genes that are included in KEGG’s Pathways
in cancer (the target pathway for Nintedanib). Sectors and chords represent the genes and
associations between the genes in the network, respectively. Red sectors represent genes
known to be associated to IPF disease. Sectors representing the Nintedanib target genes
are green.
of lung cancers), squamous cell carcinoma (25% of lung cancers), and large cell carcinoma
(10% of lung cancers) are three main subtypes of NSCLC.
As shown in Panel A of Figure 3, given a ranked-list of drugs (drug instances) obtained by applying our approach on a disease dataset, a score for drug Drugx is defined as
Score(Drugx ) = a − b, where terms a and b denote the number of already FDA-approved
drugs (gold standards) that are ranked worse and better than Drugx , respectively. Panel
B in this figure shows the computed scores for a number of top-ranked dugs from nonsmall cell lung cancer (NSCLC) results. In total, there are 8 FDA-approved drugs for

35

Figure 7: The chord diagram represents the subnetwork of DDN for Saracatinib. In order to
obtain this subnetwork, we used IPF-associated genes that are included in KEGG’s Pathways
in cancer (the target pathway for Nintedanib). Sectors and chords represent the genes and
associations between the genes in the network, respectively. Red sectors represent genes
known to be associated to IPF disease. Sectors representing the Nintedanib target genes
are green.
NSCLC in our drug input list. For instance, the score assigned to GSM1740080_sunitinib
for the GSE11969-adenocarcinoma dataset is 6, as there is only one FDA-approved drug
(highlighted with green) ranked better than GSM1740080_sunitinib and there are 7 FDAapproved drugs ranked below it (7-1=6). A score of 8 means that each candidate ranked
higher than all 8 instances of FDA-approved drugs. Table II in Panel B summarizes the
scores assigned to three drug instances: GSM1741743_sirolimus, GSM1738326_mocetinostat,
and GSM1740080_sunitinib using four NSCLC datasets. We then calculate an average
score for each drug across different disease datasets, and different instances, if there are
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Figure 8: Drug-drug network is generated using the known knowledge of drugs target
pathways, obtained from KEGG. Circles and rectangles correspond to drugs and target
pathways, respectively. Drugs are connected to each other based on their common target
pathways. Nintedanib (shown with green circle) is FDA-approved for treatment of IPF.
Pathways in cancer is known as the target pathway for Nintedanib.

Figure 9: Drug-drug network is generated using the known knowledge of drugs target
genes, obtained from KEGG and Drugbank [287]. Circles and rectangles correspond to
drugs and target genes, respectively. Drugs are connected to each other based on their
common target genes. Nintedanib (shown with green circle) is FDA-approved for treatment of IPF. VEGFR(1,2,3), PDGFR (α,β), FGFR (1,2,3), SRC, FLT3, and KIT are known to
be target genes of Nintedanib [91, 103, 131, 171, 214, 254, 289].
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multiple instances for that drug. This is shown in Figure 2.
We select the top 5% of drugs ranked lists obtained by applying our approach on disease
datasets and rank such drugs based on the scores computed by the systematic method,
from highest to the lowest.
Gold standards: Gefitinib and Crizotinib are the FDA-approved drugs for treatment
of NSCLC. These drugs are included in our list of input drugs from LINCS. On all NSCLC
datasets, three computational approaches were compared in terms of their ability to highly
rank the instances of Gefitinib and Crizotinib that exist in the LINCS drug database.
Erlotinib is used as the maintenance treatment of locally advanced or metastatic NSCLC
patients with no progress in their disease after four cycles of platinum-based first-line
chemotherapy. It is also indicated after failure of at least one prior chemotherapy regimen
in patients with NSCLC. Since Erlotinib is limited to very specific patients with NSCLC and
none of our datasets fulfill such limitations, we did not consider it as the gold standard.
However, the proposed approach is significantly better than the other two approaches even
if Erlotinib were to be included as the gold standard.
Tables 9–12 show the results obtained on four NSCLC datasets using: i) the proposed
approach, ii) the drug-disease approach, and iii) the anti-correlation approach. The FDAapproved drugs for NSCLC are highlighted in green.
We selected the top 5% of drugs ranked lists obtained by applying the proposed approach using 4 NSCLC datasets. As shown in Table 8, these drugs are ranked according to
the scores computed by the systematic method from the highest to the lowest. The sum of
the scores assigned to Gefitinib and Crizotinib (the FDA-approved drugs for NSCLC) is 0.
Drugs with the same scores are sorted based on their average ranks in drugs ranked lists.
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In this analysis, the scores computed by our systematic method can be further normalized based on dividing each score by the total number of FDA-approved drug instances for
the disease of interest (8 FDA-approved drug instances for NSCLC). Therefore, the scores
calculated for each drug across different diseases will be in the same range (-1,1).
Table 8: The top 5% of drugs obtained from the result of the proposed approach. These
drugs are ranked based on the scores generated by the systematic method. The * denotes
the drugs that are currently FDA-approved but for other indications. Gefitinib and Crizotinib, as highlighted with green, are FDA-approved for the treatment of NSCLC. Drugs
with the same scores are sorted based on their average ranks in drugs ranked lists. In this
analysis, the scores computed by our systematic method can be further normalized based
on dividing each score by the total number of FDA-approved drug instances for the disease
of interest (8 FDA-approved drug instances for NSCLC). Therefore, the scores calculated
for each drug across different diseases will be in the same range (-1,1).
Drug
Sunitinib *
Mocetinostat
Gefitinib
Roscovitine
Sirolimus *
Enzastaurin *
Crizotinib
Everolimus *
Ponatinib *
Saracatinib
Rucaparib *
Dasatinib *
Linifanib
Mitoxantrone *

Score
4.625
2.75
1.75
-1
-1
-1.75
-1.75
-2
-2.25
-2.25
-3.125
-3.375
-3.625
-4.625

Proposed candidates: We propose the FDA-approved drugs: Sunitinib (p = 0.0009),
Sirolimus (p = 0.0009), Enzastaurin (p = 0.0009), Everolimus (p = 0.001), and Ponatinib
(p = 0.004) as repurposing candidates for treatment of NSCLC. Although Mocetinostat,
Roscovitine, and Saracatinib are not approved by FDA yet, they can be prioritized for
further investigations.
As discussed earlier, Sunitinib is an oral, small-molecule that inhibits RTKs, including
VEGFR and PDGFR. Recent clinical trials have reported that Sunitinib has the provocative
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single-agent activity in previously treated patients with recurrent and advanced NSCLC [189,
251]. Sunitinib has completed the phase II of clinical trials for treatment of patients with
NSCLC (ClinicalTrials.gov IDs: NCT00372775, NCT00092001, NCT00864721). The phase
III of clinical trials on Sunitinib as a potential maintenance therapy in NSCLC patients has
been completed. These patients had received four cycles of platinum-based chemotherapy
without disease progression. The result of the trials has not published yet (ClinicalTrials.gov ID: NCT00693992).
Sirolimus, also known as Rapamycin, is a potent immunosuppressant that inhibits
mammalian target of rapamycin (mTOR). The positive effect of Sirolimus in inhibiting the
growth and progression of NSCLC is supported by several clinical studies [30, 77, 90, 234].
The phase I/II clinical trials have been launched to test the efficiency of Sirolimus in
combination with Pemetrexed for treating patients with NSCLC (ClinicalTrials.gov ID:
NCT01061788). The phase I clinical trials of Sunitinib and Sirolimus confirm that this
combination is well-tolerated and warrants further investigation in advanced NSCLC (ClinicalTrials.gov ID: NCT00555256) [282].
Everolimus is a derivative of rapamycin (Sirolimus). It is approved by FDA for treatment of several conditions, including breast cancer, advanced renal cell carcinoma, renal
angiomyolipoma, and tuberous sclerosis. It has shown antitumor activity both as the single
agent and in combination with other agents in treatment of patients with NSCLC. Several
clinical trials support the efficacy of Everolimus in treatment of NSCLC [90, 212, 252, 271]
(ClinicalTrials.gov ID: NCT00096486).
Increased levels of protein kinase C (PKC) and AKT are known to be associated with
the poor prognosis in NSCLC [57, 192]. Enzastaurin, an oral serine/threonine kinase
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inhibitor, suppresses PKC and protein kinase B/AK transforming (AKT) signaling, induces
tumor cell apoptosis, and inhibits the proliferation and angiogenesis [192]. Enzastaurin is
proven to inhibit the growth of NSCLC cell lines [184, 192, 261]. The Phase II evaluation
of Enzastaurin as the second-and third- line treatment for NSCLC has completed with
promising results (ClinicalTrials.gov ID: NCT00105092).
Fibroblast growth factor receptors (FGFRs) are known to be overexpressed in NSCLC [23,
235]. Ponatinib is proven to be effective against the FGFR1 kinase in 8p11 myeloproliferative syndrome (EMS) [45]. In particular, It has been shown that Ponatinib can suppress
cell growth in NSCLC cell lines [218, 263]. Several studies reported that RET fusions are
viable targets in NSCLC [44, 81, 84]. The phase II of the clinical trial (ClinicalTrials.gov ID:
NCT01813734) is currently evaluating the safety and the effectiveness of the RET inhibitor
Ponatinib in treating patients with NSCLC.
It has been reported that HDAC inhibitor Mocetinostat may restore normal cell function and reduce or inhibit the tumor growth [187]. A phase 1/2 clinical trial of Mocetinostat, in combination with Durvalumab is currently ongoing in treating patients with solid
tumors and NSCLC to evaluate the safety and efficacy of this combination [98] (ClinicalTrials.gov IDs: NCT02805660). Another clinical trial is currently undergoing to evaluate
the clinical activity of Nivolumab in combination with three separate drugs, Glesatinib,
Sitravatinib, or Mocetinostat in NSCLC (ClinicalTrials.gov ID: NCT02954991, phase II).
Roscovitine is an experimental drug in the class of pharmacological cyclin-dependent
kinase (CDK) inhibitors. Current clinical studies [56, 195] suggest the combination of
Roscovitine and Belinostat in treating patients with NSCLC. The phase II study of Roscovitine as a single agent in previously-treated patients with non-small cell lung cancer has
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Table 9: A comparison between the results of three approaches: proposed, drug-disease,
anti-correlation using GSE11969-adenocarcinoma dataset (the top 10 drugs). The p-values
for Wilcoxon rank sum test comparing the results of the proposed approach with drugdisease and anti-correlation approaches are 0.01 and 0.005, respectively. Drugs highlighted with green are FDA-approved for the treatment of NSCLC. The * denotes the drugs
that are currently FDA-approved but for other indications.
GSE11969-adenocarcinoma
Proposed
Drug-disease
GSM1741743_sirolimus*
GSM1746780_erlotinib*

Anti-correlation
GSM1737411_NVPBGT226
GSM1741104_sunitinib*
GSM1738326_mocetinostat GSM1739358_mocetinostat
GSM1738326_mocetinostat GSM1739358_mocetinostat GSM1741104_sunitinib*
GSM1739358_mocetinostat GSM1741104_sunitinib*
GSM1740576_BI-2536
GSM1746613_enzastaurin GSM1745191_NVPGSM1738326_mocetinostat
BEZ235
GSM1742552_linifanib
GSM1745674_dovitinib
GSM1740923_BI-2536
GSM1742645_gefitinib
GSM1742797_palbociclib* GSM1737409_NVPBGT226
GSM1740080_sunitinib*
GSM1745194_NVPGSM1742797_palbociclib*
BEZ235
GSM1737700_rucaparib*
GSM1746864_radicicol
GSM1737349_everolimus*
GSM1744393_gefitinib
GSM1741767_vorinostat* GSM1745194_NVPBEZ235
terminated with no data reported (ClinicalTrials.gov ID: NCT00372073).
Saracatinib is an inhibitor of SRC kinases that may improve NSCLC treatment [227,
228, 309]. It is undergoing phase II of clinical trials in treatment of patients with NSCLC
(NCT00638937).
2.5.3

Prostate cancer

We use three different prostate cancer datasets. The first dataset is obtained by comparing gene expression levels between prostate tissues from 6 prostate cancer samples with
6 healthy samples using Affymetrix Human Genome U133 Plus2.0 Array. This dataset is
available via GEO (GSE26910) [209]. GSE6919 is the second dataset that compares 65 primary prostate cancer samples with 18 healthy samples using Affymetrix Human Genome
U95A Version 2 Array [43, 303]. The third dataset is the result of comparing gene expres-
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Table 10: A comparison between the results of three approaches: proposed, drug-disease,
anti-correlation using GSE11969-large cell carcinoma dataset (the top 10 drugs). The pvalues for Wilcoxon rank sum test comparing the results of the proposed approach with
drug-disease and anti-correlation approaches are 0.001 and 0.0005, respectively. Drugs
highlighted with green are FDA-approved for the treatment of NSCLC. The * denotes the
drugs that are currently FDA-approved but for other indications.
GSE11969-large cell carcinoma
Proposed
Drug-disease
GSM1741743_sirolimus*
GSM1745191_NVPBEZ235
GSM1741104_sunitinib*
GSM1738326_mocetinostat
GSM1739358_mocetinostat GSM1739358_mocetinostat
GSM1738326_mocetinostat GSM1745194_NVPBEZ235
GSM1740080_sunitinib*
GSM1745149_GDC-0980

Anti-correlation
GSM1737411_NVPBGT226
GSM1740576_BI-2536
GSM1740923_BI-2536
GSM1745191_NVPBEZ235
GSM1745194_NVPBEZ235
GSM1741800_mitoxantrone*GSM1741767_vorinostat* GSM1739358_mocetinostat
GSM1744393_gefitinib
GSM1737642_mocetinostat GSM1745149_GDC-0980
GSM1742645_gefitinib
GSM1738308_entinostat
GSM1737409_NVPBGT226
GSM1746613_enzastaurin GSM1742797_palbociclib* GSM1737410_NVPBGT226
GSM1742878_dasatinib*
GSM1739435_belinostat*
GSM1741767_vorinostat*
sion levels between 69 prostate cancer patients and 18 normal patients using Affymetrix
Human Genome U133A 2.0 Array. This dataset is available in GEO (GSE6956) [277].
Gold standard: Nilutamide is the FDA-approved drug for the treatment of prostate
cancer. This antiandrogen drug is included in our list of input drugs from Connectivity
Map. Prostate cancer mostly depends on the androgen for the growth and survival. Nilutamide is known to block the action of androgens of adrenal and testicular origin that
stimulate the growth of the normal and malignant prostatic tissue [128].
Tables 14–16 show the results obtained on 3 prostate cancer datasets using: i) the
proposed approach, ii) the drug-disease approach, and iii) the anti-correlation approach.
We selected the top 5% drugs from the drugs ranked lists obtained by applying the
proposed approach on 3 prostate cancer datasets. As shown in Table 13, these drugs are
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Table 11: A comparison between the results of three approaches: proposed, drug-disease,
anti-correlation using GSE11969-squamous cell carcinoma dataset (the top 10 drugs). The
p-values for Wilcoxon rank sum test comparing the results of the proposed approach with
drug-disease and anti-correlation approaches are 0.001 and 0.0003, respectively. Drugs
highlighted with green are FDA-approved for the treatment of NSCLC. The * denotes the
drugs that are currently FDA-approved but for other indications.
GSE11969-squamous cell carcinoma
Proposed
Drug-disease
Anti-correlation
GSM1741743_sirolimus*
GSM1739358_mocetinostat GSM1737411_NVPBGT226
GSM1741104_sunitinib*
GSM1738326_mocetinostat GSM1740576_BI-2536
GSM1740080_sunitinib*
GSM1746780_erlotinib*
GSM1745149_GDC-0980
GSM1738326_mocetinostat GSM1742797_palbociclib* GSM1745194_NVPBEZ235
GSM1746613_enzastaurin GSM1737642_mocetinostat GSM1739358_mocetinostat
GSM1739358_mocetinostat GSM1742706_alvocidib
GSM1741767_vorinostat*
GSM1744393_gefitinib
GSM1745912_neratinib*
GSM1737410_NVPBGT226
GSM1742878_dasatinib*
GSM1737967_entinostat
GSM1737409_NVPBGT226
GSM1740081_sunitinib*
GSM1738308_entinostat
GSM1745191_NVPBEZ235
GSM1740917_saracatinib
GSM1737624_entinostat
GSM1741769_sirolimus*

Table 12: A comparison between the results of three approaches: proposed, drug-disease,
anti-correlation using GSE32863 dataset (the top 10 drugs). The p-values for Wilcoxon
rank sum test comparing the results of the proposed approach with drug-disease and anticorrelation approaches are 0.007 and 0.007, respectively. Drugs highlighted with green
are FDA-approved for the treatment of NSCLC. The * denotes the drugs that are currently
FDA-approved but for other indications.
GSE32863-adenocarcinoma
Proposed
GSM1741743_sirolimus*
GSM1738326_mocetinostat
GSM1741104_sunitinib*
GSM1740080_sunitinib*
GSM1739358_mocetinostat
GSM1742878_dasatinib*
GSM1744393_gefitinib
GSM1740301_ponatinib*
GSM1740081_sunitinib*
GSM1742552_linifanib

Drug-disease
Anti-correlation
GSM1738326_mocetinostat GSM1738326_mocetinostat
GSM1739358_mocetinostat GSM1739453_decitabine*
GSM1743209_nintedanib* GSM1746780_erlotinib*
GSM1746780_erlotinib*
GSM1739358_mocetinostat
GSM1746881_mitoxantrone*GSM1742878_dasatinib*
GSM1746893_radicicol
GSM1743210_nintedanib*
GSM1742797_palbociclib* GSM1742797_palbociclib*
GSM1740576_BI-2536
GSM1742706_alvocidib
GSM1740298_ponatinib*
GSM1744393_gefitinib
GSM1741767_vorinostat* GSM1740576_BI-2536
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ranked according to the scores computed by the systematic method from the highest to
the lowest. The score assigned to Nilutamide is 0. Drugs with the same scores are sorted
based on their average ranks in drugs ranked lists.
Table 13: The top 5% drugs obtained from the result of our repurposing approach. These
drugs are ranked based on the scores generated by the systematic method. The * denotes
the drugs that are currently FDA-approved but for other indications. The score for Nilutamide, the FDA-approved drug for prostate cancer, is 0. Drugs with the same scores are
sorted based on their average ranks in drugs ranked lists.
Drug
Podophyllotoxin *
Nilutamide
Acetylsalicylic acid *
Papaverine *
Mefloquine *
Vorinostat *
Sirolimus *
Alprostadil *
Glibenclamide *
Oxyphenbutazone (discontinued/withdrawn)
Phenelzine *
Methylergometrine *
Parthenolide
Primaquine *
Phenoxybenzamine *
Etoposide *
Captopril *
Trichostatin A
Fluorometholone *

Score
0.33
0
-0.33
-0.33
-0.33
-0.33
-0.33
-0.33
-0.33
-0.33
-0.33
-0.33
-0.33
-0.33
-0.67
-0.67
-0.67
-0.67
-1

Proposed candidates: In this case study, we chose Podophyllotoxin (p = 0.2), Acetylsalicylic acid (p = 0.2), Papaverine (p = 0.01), Mefloquine (p = 0.03), Vorinostat (p =
0.1), and Sirolimus (p = 0.06) for further evaluations.
Podophyllotoxin is a natural product found in podophyllin resin from the roots of
podophyllum plants. Podophyllotoxin and its derivatives, including Deoxypodophyllotoxin, are reported to have significant anti-tumor effects in a number of cancers [25, 48,
53, 88, 137, 159]. A recent study demonstrated that Deoxypodophyllotoxin inhibits the
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cell proliferation and induces the cell apoptosis in human prostate cancer cells through
the Akt/p53/Bax/PTEN signaling pathway, suggesting that Deoxypodophyllotoxin could
be used as a novel chemotherapeutic drug for human prostate cancer [109].
Acetylsalicylic acid (Aspirin) is a nonsteroidal anti-inflammatory drug that is used for
the temporary relief of different forms of pain, and the inflammation associated with various conditions. It is also indicated to decrease the risk of death and myocardial infarction
in patients with chronic coronary artery disease. Recent findings confirm that the long duration regular Aspirin use modestly reduces the risk of prostate cancer [52, 97, 118, 160,
188, 229, 249]. Aspirin is also reported to affect the proliferation, apoptosis, resistance
and metastasis of prostate cancer cell lines, suggesting the further evaluation of the signaling cascades activated by Aspirin in order to improve diagnosis, prognosis and treatment
of prostate cancer [29]. According to these findings, Aspirin can be used for both prevention and treatment purposes in prostate cancer (ClinicalTrials.gov IDs: NCT02757365,
NCT03103152, NCT02804815).
Papaverine is a nonxanthine phosphodiesterase inhibitor that is indicated for the relief of the cerebral and peripheral ischemia. It induces morphologic differentiation and
suppresses the proliferation of human prostate cancer cell [89]. Papaverine is reported
to have antitumor effects in prostate cancer by inducing significant, highly selective and
dose-dependent cytotoxic effects in cancer cells [112, 236].
Mefloquine (MQ) is a prophylactic anti-malarial drug which acts as a blood schizonticide and can be a potential treatment for prostate cancer. Recent findings indicate that
MQ has anticancer effects in PC3, which is the most commonly used prostate cancer cell
line [294, 295]. MQ has been reported to be potent in killing cancer cells in vitro, sug-
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Table 14: A comparison between the results of three approaches: proposed, drug-disease,
anti-correlation using GSE26910 dataset (the top 10 drugs). The ranks of Nilutamide,
the FDA-approved drug for prostate cancer, in the proposed approach, drug-disease and
anti-correlation approaches results are 9, 13, and 63 , respectively. Drug highlighted with
green is FDA-approved for the treatment of prostate cancer. The * denotes the drugs that
are currently FDA-approved but for other indications.
GSE26910
Proposed
mefloquine_5724 *
mefloquine_2210 *
podophyllotoxin_2540
vorinostat_6179 *

Drug-disease
luteolin_3041
etoposide_1626 *
vorinostat_6939 *
phenoxybenzamine_5248
*
phenoxybenzamine_5613 puromycin_3310
*
oxyphenbutazone_6844 ciclopirox_2456 *
parthenolide_2885
parthenolide_5530

vorinostat_6179 *
anisomycin_1304 *

nilutamide_5362

lycorine_3808

Anti-correlation
vorinostat_6179 *
parthenolide_5530
parthenolide_2885
tanespimycin_2666
phenoxybenzamine_5248
*
phenoxybenzamine_5613
*
doxazosin_3024 *
mycophenolic
acid_2857 *
etoposide_3241 *

gested as the chemotherapeutic agent for treatment of glioblastoma and breast cancer
cells [85, 247].
Vorinostat is a histone deacetylase (HDAC) inhibitor approved by FDA for the treatment of patients with cutaneous T-cell lymphoma (CTCL). Inhibition of the HDAC has
resulted in decreasing the tumor growth and reducing cell proliferation in prostate cancer, suggesting that Vorinostat could be a potential drug for treatment of prostate cancer [32, 39, 66, 130] (ClinicalTrials.gov IDs: NCT00330161, NCT00589472).
The initial preclinical and clinical studies show that the mTOR inhibition Sirolimus can
be useful in treating patients with prostate cancer [9, 40, 55, 114, 215]. Sirolimus and its
combination with other drugs are undergoing clinical trials in treatment of patients with
prostate caner (NCT00311623, NCT02565901).
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Table 15: A comparison between the results of three approaches: proposed, drug-disease,
anti-correlation using GSE6919 dataset (the top 10 drugs). The ranks of Nilutamide, the
FDA-approved drug for prostate cancer, in the proposed approach, drug-disease and anticorrelation approaches results are 7, 81, and 129, respectively. Drugs highlighted with
green are FDA-approved for the treatment of prostate cancer. The * denotes the drugs that
are currently FDA-approved but for other indications.
GSE6919
Proposed
papaverine_1755 *
vorinostat_6179 *
etoposide_3241 *
alprostadil_2938 *
podophyllotoxin_2540*
methylergometrine_1607
nilutamide_5362
fluorometholone_6247
*
colchicine_1598 *
acetylsalicylic
acid_1042 *

Drug-disease
alvespimycin_1638
daunorubicin_4983 *
tanespimycin_986
doxorubicin_5671 *
alvespimycin_993
mitoxantrone_3232 *
etoposide_3241 *
parthenolide_5530

Anti-correlation
doxorubicin_3291 *
doxorubicin_5671 *
daunorubicin_4983 *
mitoxantrone_3232 *
rifabutin_3873 *
alvespimycin_1638
alvespimycin_993
oxyphenbutazone_6844

ciclopirox_3317 *
mitoxantrone_5354 *

mitoxantrone_5354 *
vorinostat_6939 *

Table 16: A comparison between the results of three approaches: proposed, drug-disease,
anti-correlation using GSE6956 dataset (the top 10 drugs). The ranks of Nilutamide, the
FDA-approved drug for prostate cancer in the proposed approach, drug-disease and anticorrelation approaches results are 15, 141, and 90, respectively. The * denotes the drugs
that are currently FDA-approved but for other indications.
GSE6956
Proposed
acetylsalicylic
acid_1042 *
captopril_1988 *
sirolimus_1080 *
glibenclamide_1546 *
phenelzine_4360 *
sirolimus_987 *
trichostatin A_5017
primaquine_4845 *
paclitaxel_6720
ajmaline_1749 *

Drug-disease
phenelzine_4360 *

Anti-correlation
phenelzine_4360 *

rifabutin_4349 *
trichostatin A_5017
captopril_1988 *
ambroxol_6719 *
metaraminol_2298 *
sirolimus_1080 *
picrotoxinin_2161 *
cyproheptadine_6740 *
primaquine_4845 *

rifabutin_4349 *
primaquine_4845 *
norfloxacin_7283 *
flunixin_2552
captopril_1988 *
sirolimus_987 *
trichostatin A_5017
calmidazolium_906
ambroxol_6719 *

48

2.5.4

Breast cancer

We obtained six breast cancer datasets, GSE1299 [175] and GSE28645 [278], and
GSE65194 (subtypes: Her2, luminalA, luminalB, triple negative) [165, 166, 170] from
Gene Expression Omnibus (GEO). Datasets GSE1299 and GSE65194 (Her2, luminalA, luminalB, triple negative) consist of two groups of samples such as disease and control,
while the dataset GSE28645 is a gene expression dataset that consists of two groups of
samples: treated (by tamoxifen) and untreated. It is well-known that choices of the treatment and the ultimate success for breast cancer highly depend on its specific type [86],
that is categorized as:
• Hormone receptor positive (estrogen and/or progesterone receptor positive) or hormone receptor negative (estrogen and/or progesterone receptor negative)
• Human epidermal growth factor receptor (HER2/neu) positive or HER2/neu negative
• Triple negative (all estrogen receptor, progesterone receptor, and HER2/neu are negative)
Other factors that affect the prognosis and treatment options include: stage of the
cancer, levels of estrogen receptor, progesterone receptor, or HER2/neu in the tumor tissue,
the growth rate of the tumor, the recurrence rate, patient’s age, and menopausal status.
Gold standard: Fulvestrant, Paclitaxel, Methotrexate are FDA-approved drugs for the
treatment of breast cancer. These drugs are included in our list of input drugs from Connectivity Map. Table 17 represents the target genes and activity of these drugs, obtained
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from KEGG and Drugbank [287]. Tables 19–24 show the results obtained on 6 breast cancer datasets using: i) the proposed approach, ii) the drug-disease approach, and iii) the
anti-correlation approach.
We selected the top 5% drugs from the drugs ranked lists obtained by applying the
proposed approach on 6 breast cancer datasets. These drugs are ranked according to the
scores computed by the systematic method from the highest to the lowest. Table 18 shows
the rank-ordered list of such drugs according to their score.
Proposed candidates: For this disease, we propose Captopril (p = 0.001), Glibenclimiade (p = 0.0009), Fluorometholone (p = 0.005), Etoposide (p = 0.01), Colchicine
(p = 0.001), and Tretinoin (p = 0.0009) as repurposing candidates for treatment of breast
cancer.
Captopril is indicated for treatment of hypertension, congestive heart failure, and kidney problems caused by diabetes. Recent clinical studies confirm the potential antineoplastic effect of Captopril in cancer [123, 129, 144, 225, 230]. The phase I/II clinical trial
(ClinicalTrials.gov ID: NCT00086723) evaluates the activity of Captopril and the tissue
plasminogen activator (a blood factor/protein orchestrating the breakdown of blood clot)
in treating patients with progressive metastatic cancer. Specifically, Captopril is proven to
play a role in prevention and regression of the tamoxifen-induced resistance of breast cancer cell line MCF-7 [185], suggesting that it can be used in combination with Tamoxifen to
overcome such resistance.
Glibenclimiade is an antidiabetic drug that is used as an adjunct to diet and exercise for treatment of patients with type 2 diabete. Glibenclamide is proven to be a tumor
growth inhibitor [2, 202, 213, 224, 299]. It is considered as a promising antitumor drug
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in several cancers, including breast cancer. In particular, the cytostatic effect of Glibenclimiade by inducing G0/G1 arrest has been clearly demonstrated in MDA-MB-231 cells.
Additionally, the study of its effect in combination with Doxorubicin suggests the novel
role of Glibenclimiade as an adjuvant in breast cancer treatment [190].
Fluorometholone and Clobetasol are in the family of glucocorticoids (GCs). GCs have
shown some modest benefits in treatment of breast cancer. However, their underlying
mechanism in breast cancer is not well-understood [127, 132, 155]. GCs are also used
as an adjuvant during chemotherapy or radiotherapy to reduce the side effects in cancer
treatment [290].
Etoposide is approved by FDA for the treatment of refractory testicular tumors, and
usually used in combination with other chemotherapeutic agents. It is also used as the
first line treatment in small cell lung cancer patients. The positive therapeutic effect of
Etoposide in patients with breast cancer is experimentally validated by clinical studies [18,
306] (ClinicalTrials.gov identifiers: NCT01492556, NCT00026949, and NCT01589159).
The histone deacetylase (HDAC) inhibitor Trichostatin A (TSA) is another drug we
suggest for treatment of breast cancer. It is used as an antifungal antibiotic that is found
to be useful both as the single agent and in combination with other agents in cancer treatment [119, 120, 134, 147, 182, 223, 257]. Current studies confirm the potent antitumor
activity of TSA against breast cancer [7, 221, 272, 293, 298].
Colchicine is found in crocuses and primarily indicated to treat gout. It has been also
used for treatment of familial mediterranean fever. A 12-year study in male patients with
gout shows that patients who used Colchicine had a significantly lower risk of cancers
than patients who never used Colchicine [145]. Another study in mice models shows
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that Colchicine can induce immunogenic cell death in tumor cells, suggesting the future
clinical evaluation for Colchicine as a cancer vaccine [284]. Colchicine is reported to have
an anticancer effect on human gastric cancer cell lines [156]. In particular, a recent study
indicates that it can inhibit proliferation of the breast cancer MCF-7 cells and induce cell
apoptosis, where the intensity of the effect depends on the time and dosage [255].
Tretinoin, all-trans-retinoic acid (ATRA), is the FDA-approved drug for the treatment
of acne, photodamaged skin, and keratinization disorders. It is also used to treat acute
promyelocytic leukemia (APL). The usefulness of ATRA in treatment of breast cancer has
been independently validated in study by Bhat-Nakshatri et al. [27]. Moreover, antiproliferative, cyto-differentiating and apoptotic effects of ATRA are demonstrated in [33,
82, 256], suggesting the effectiveness of ATRA in treatment of breast cancer tumors with
high retinoic acid receptor alpha (RARα) / retinoic acid receptor gamma (RARγ) ratios.
Estrogen receptor-positive and Her2/neu-positive breast cancers are two subtypes of breast
cancer that can be optimal targets for ATRA [157, 199].
Table 17 represents the target genes and activity of these drugs, obtained from KEGG
and Drugbank [287].
Table 17: The FDA-approved drugs for breast cancer.
Drug
Target genes
Fulvestrant
ESR (1,2)
Methotrexate DHFR
Paclitaxel
BCL2, TUBB1, NR1I2, MAP (2,4), MAPT

Activity
Estrogen receptor antagonist
Antimetabolite
Tubulin depolymerization inhibitor

Tables 19–24 show the results obtained on 6 breast cancer datasets using: i) the proposed approach, ii) the drug-disease approach, and iii) the anti-correlation approach. The
FDA-approved drugs for breast cancer are highlighted in green. Interestingly, all two in-
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stances of Fulvestrant that are all exposures of the same cell line (MCF7) (with the same
dosage) are highly ranked by our approach in all datasets. MCF7 cell line is an ideal
model for hormone therapy that was established in 1973 at the Michigan Cancer Foundation [253].
We selected the top 5% drugs from the drugs ranked lists obtained by applying the
proposed approach on 6 breast cancer datasets. These drugs are ranked according to the
scores computed by the systematic method from the highest to the lowest. Table 18 shows
the rank-ordered list of such drugs according to their score.
Table 18: The top 5% drugs obtained from the result of our repurposing approach. These
drugs are ranked based on the scores generated by the systematic method. The * denotes
the drugs that are currently FDA-approved but for other indications. Fulvestrant, Paclitaxel, and Methotrexate highlighted with green, are FDA-approved for the treatment of
breast cancer. The sum of the scores assigned to these drugs is 0. Drugs with the same
scores are sorted based on their average ranks in drugs ranked lists. In this analysis, the
scores computed by our systematic method can be further normalized based on dividing
each score by the total number of FDA-approved drug instances for the disease of interest.
Therefore, the scores calculated for each drug across different diseases will be in the same
range (-1,1).
Drug
Fulvestrant
Paclitaxel
Captopril *
Methotrexate
Glibenclamide *
Fluorometholone *
Clobetasol
Trichostatin A
Etoposide *
Colchicine *
Tretinoin *
Alvespimycin
Resveratrol
Methylergometrine

Score
1.33
0
-0.33
-1.33
-2
-2.33
-2.67
-2.83
-3.33
-3.67
-3.67
-3.67
-3.67
-4
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Table 19: A comparison between the results of three approaches: proposed, drug-disease,
anti-correlation using GSE65194-Her2 dataset (the top 10 drugs). The p-values for
Wilcoxon rank sum test comparing the results of the proposed approach with drug-disease
and anti-correlation approaches are 0.01 and 0.02, respectively. Drugs highlighted with
green are FDA-approved for the treatment of breast cancer. The * denotes the drugs that
are currently FDA-approved but for other indications. Such drugs can be used off-label.
GSE65194-Her2
Proposed
captopril_1988 *
paclitaxel_6720
fulvestrant_1630
fulvestrant_985
etoposide_3241 *
captopril_4585 *

Drug-disease
glibenclamide_1546
danazol_2038 *
cimetidine_1884 *
domperidone_2655
trichostatin A_5017
ipratropium
bromide_1769
bro- etoposide_3241 *

ipratropium
mide_1769
metoclopramide_2353 *
domperidone_2655
methotrexate_5000

ajmaline_1749 *
methotrexate_5000
resveratrol_841 *

Anti-correlation
glibenclamide_1546
cimetidine_1884 *
danazol_2038 *
ajmaline_1749 *
domperidone_2655
ipratropium
bromide_1769
acepromazine_1777
nilutamide_5362
genistein_5232
captopril_1988 *

Table 20: A comparison between the results of three approaches: proposed, drug-disease,
anti-correlation using GSE65194-LuminalA dataset (the top 10 drugs).The p-values for
Wilcoxon rank sum test comparing the results of the proposed approach with drug-disease
and anti-correlation approaches are 0.03 and 0.04, respectively. Drugs highlighted with
green are FDA-approved for the treatment of breast cancer. The * denotes the drugs that
are currently FDA-approved but for other indications. The proposed approach was the only
one who was able to rank the FDA-approved drugs in the top 10.
GSE65194-LuminalA
Proposed
fulvestrant_985
fulvestrant_1630
captopril_1988 *
fluorometholone_6247
*
glibenclamide_1546 *
captopril_4585 *
paclitaxel_6720
vorinostat_6939 *
cimetidine_1884 *
trichostatin A_5017

Drug-disease
glibenclamide_1546 *
domperidone_2655
cimetidine_1884 *
danazol_2038 *

Anti-correlation
domperidone_2655
glibenclamide_1546 *
cimetidine_1884 *
ipratropium
bromide_1769
bro- danazol_2038 *

ipratropium
mide_1769
trichostatin A_5017
nilutamide_5362 *
ethosuximide_1433 *
ajmaline_1749 *
genistein_5232

nilutamide_5362
ajmaline_1749 *
genistein_5232
acepromazine_1777
ethosuximide_1433 *
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Table 21: A comparison between the results of three approaches: proposed, drug-disease,
anti-correlation using GSE65194-LuminalB dataset (the top 10 drugs). The p-values for
Wilcoxon rank sum test comparing the results of the proposed approach with drug-disease
and anti-correlation approaches are 0.02 and 0.01, respectively. Drugs highlighted with
green are FDA-approved for the treatment of breast cancer. The * denotes the drugs that
are currently FDA-approved but for other indications.
GSE65194-LuminalB
Proposed
fulvestrant_985
fulvestrant_1630
paclitaxel_6720
captopril_1988 *
trichostatin A_5017
phenelzine_4360 *
fluorometholone_6247
*
valproic acid_2700 *
etoposide_3241 *
glibenclamide_1546 *

Drug-disease
glibenclamide_1546 *
cimetidine_1884 *
danazol_2038 *
ajmaline_1749 *
trichostatin A_5017
domperidone_2655
etoposide_3241 *
ipratropium
mide_1769
sirolimus_1080 *
methotrexate_5000

Anti-correlation
glibenclamide_1546 *
cimetidine_1884 *
danazol_2038 *
ajmaline_1749 *
domperidone_2655
ipratropium
bromide_1769
fluorometholone_6247
*
bro- sirolimus_1080 *
acepromazine_1777
nilutamide_5362

Table 22: A comparison between the results of three approaches: proposed, drug-disease,
anti-correlation using GSE65194-Triple Negative dataset (the top 10 drugs). The p-values
for Wilcoxon rank sum test comparing the results of the proposed approach with drugdisease and anti-correlation approaches are 0.03 and 0.007, respectively. Drugs highlighted with green are FDA-approved for the treatment of breast cancer. The * denotes the
drugs that are currently FDA-approved but for other indications.
GSE65194-Triple Negative
Proposed
Drug-disease
captopril_1988 *
glibenclamide_1546 *
paclitaxel_6720
danazol_2038 *
etoposide_3241 *
cimetidine_1884 *
clobetasol_6835
ajmaline_1749 *
methotrexate_5000
methotrexate_5000
fulvestrant_985
glibenclamide_1546 *
fulvestrant_1630
captopril_4585 *
domperidone_2655

resveratrol_841 *
ipratropium
mide_1769
trichostatin A_5017
acepromazine_1777
wortmannin_1023 *

Anti-correlation
glibenclamide_1546 *
danazol_2038 *
ajmaline_1749 *
cimetidine_1884 *
ipratropium
bromide_1769
domperidone_2655
bro- acepromazine_1777
etoposide_3241 *
nilutamide_5362
methotrexate_5000

55

Table 23: A comparison between the results of three approaches: proposed, drug-disease,
anti-correlation using GSE28645 dataset (the top 10 drugs). The p-values for Wilcoxon
rank sum test comparing the results of the proposed approach with drug-disease and anticorrelation approaches are 0.05 and 0.07, respectively. Drugs highlighted with green are
FDA-approved for the treatment of breast cancer. The * denotes the drugs that are currently FDA-approved but for other indications.
GSE28645
Proposed
fulvestrant_985
fulvestrant_1630
methylergometrine_1607
alvespimycin_993
colchicine_1598 *
captopril_1988 *
vorinostat_6939 *
captopril_4585 *
sirolimus_1080 *
trichostatin A_5017

Drug-disease
paclitaxel_6720
captopril_1988 *
phenelzine_4360 *
fluphenazine_6954 *
clomipramine_4487 *
rosiglitazone_4457 *
genistein_5232
astemizole_6807 *
chlorpromazine_5074 *
cimetidine_1884 *

Anti-correlation
phenelzine_4360 *
valproic acid_1181 *
paclitaxel_6720
rosiglitazone_4457 *
captopril_1988 *
troglitazone_4456 *
quercetin_2499
hyoscyamine_1424 *
clomipramine_4487 *
genistein_1176

Table 24: A comparison between the results of three approaches: proposed, drug-disease,
anti-correlation using GSE1299 dataset (the top 10 drugs). The p-values for Wilcoxon
rank sum test comparing the results of the proposed approach with drug-disease and anticorrelation approaches are 0.007 and 0.02, respectively. Drugs highlighted with green
are FDA-approved for the treatment of breast cancer. The * denotes the drugs that are
currently FDA-approved but for other indications.
GSE1299
Proposed
methotrexate_5419
resveratrol_841 *
methotrexate_5000
fulvestrant_985
tretinoin_6170 *
phenelzine_4360 *
fulvestrant_1630
tretinoin_1548 *

Drug-disease
etoposide_3241 *
ciclopirox_3317 *
resveratrol_841 *
valproic acid_1181 *
rifabutin_4349 *
ivermectin_2213 *
oxyphenbutazone_6844
methotrexate_5419

troglitazone_4456 *
rosiglitazone_4457 *

rifabutin_3873 *
wortmannin_1023 *

Anti-correlation
etoposide_3241 *
valproic acid_1181 *
rifabutin_4349 *
methotrexate_5419
resveratrol_841 *
rifabutin_3873 *
ciclopirox_3317 *
prochlorperazine_5212
*
vorinostat_6939 *
phenelzine_4360 *
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2.5.5

The relationship between pathway size and prediction accuracy

The prediction accuracy of the proposed approach does not depend on size of the KEGG
pathways, nor on the size of the drug-disease network (DDN) constructed for each drug.
In other words, a drug with a larger drug-disease network is not more likely to be ranked
higher just because of the size of its network.
In order to prove this, we calculated the Pearson correlation coefficient between the
drug’s average ranks (obtained from applying our approach on disease datasets) and their
networks size (the number of nodes) for each disease (Figure 10 and 11). If the ranking of
a drug depended on the size of its drug-disease network (e.g. the top ranked drug would
have the largest network, the second drug would have the second largest network, etc.),
then there would be a very strong correlation between the ranks and the network sizes.
In fact, the computed Pearson correlation coefficients between the ranks and the network
sizes were: 0.004 for IPF, 0.25 for NSCLC, -0.10 for breast cancer, and -0.14 for prostate
cancer. Both the low absolute values of these correlation coefficients as well as the fact
that two of them are positive and while the other two are negative show no indication of
any dependency between the pathway sizes and the predictions.
2.6

Summary
We presented a systems biology approach to discover new uses of existing FDA-approved

drugs. We take advantage of known knowledge of disease-related genes, drug targets information, and signaling pathways to discover drugs with the potential desired effects on
the given disease. We estimated a network of genes potentially perturbed by drugs and
integrate this network with drug and disease gene expression signatures to conduct a more
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Figure 10: The relationship between pathway size and prediction accuracy. In order to
investigate the relationship between pathway size and prediction accuracy, we calculated
the Pearson correlation coefficient between the drug’s average ranks and their networks
size for each disease.
powerful analysis at system level. To evaluate the proposed approach for drug repurposing, four different diseases (IPF, NSCLC, prostate cancer, and breast cancer) were analyzed
using 3 approaches: proposed, drug-disease, and anti-correlation. For each disease, there
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Figure 11: The scatter plots of the drug relative average rank vs. network size for four
diseases: IPF, NSCLC, breast cancer, and prostate cancer. The scatter plots of the drug
relative average rank vs. network size for four diseases: IPF, NSCLC, breast cancer, and
prostate cancer. The Pearson correlation coefficients between the ranks and the network
sizes were: 0.004 for IPF, 0.25 for NSCLC, -0.10 for breast cancer, and -0.14 for prostate
cancer. The low correlations show there is no indication of a dependency between the
pathway size and the predicted ranks.
is at least one FDA-approved drug that is used to treat that disease in our input drug data.
The already FDA-approved drugs for a given disease are considered as the gold standard
because such drugs successfully passed all the preclinical and clinical trials for that disease
and were demonstrated to be efficacious in each disease. The approach was validated by
its ability to identify drugs that are already approved by FDA for these conditions. We
provided evidences that support the usefulness of the proposed candidates in treatment of
IPF, NSCLC, prostate cancer, and breast cancer. In all diseases, the proposed approach was
able to rank highly the approved drugs for the given conditions. This is in contrast with
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the Sirota et al. (drug-disease) and anti-correlation approaches which were not able to
retrieve any of the FDA approved drugs at the top of their respective rankings. For many
of the proposed repurposing candidates, there is significant preliminary evidence, as well
as a number of clinical trials in progress.
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CHAPTER 3 CELL TYPE IDENTIFICATION
3.1

Problem statement
Recent advances in single-cell RNA-Seq (scRNASeq) techniques have provided tran-

scriptomes of the large numbers of individual cells (single-cell gene expression data) [61,
79, 99, 126, 168, 186, 194, 266, 280]. In particular, analyzing the diversity and evolution
of single cancer cells can enable the advances in early cancer diagnosis, and ultimately
choosing the best strategy for cancer treatment [149, 231, 244]. Furthermore, one important analysis on scRNASeq is the identification of cell types that can be achieved by
performing an unsupervised clustering method on transcriptome data [12, 13, 75, 177,
265, 291, 304, 308].
3.2

Overview of existing approaches
Clustering algorithms such as k-means and density-based spatial clustering of appli-

cations with noise (DBSCAN) [78] can identify groups of cells given the single-cell gene
expression data. However, clusters obtained by these algorithms might not be robust. Such
algorithms require non-intuitive parameters [12]. For instance, given the number of clusters, k-means iteratively assigns data points (cells) to the nearest centroids (cluster center),
and recomputes the centroids based on the predefined number of clusters. This algorithm
starts with the randomly chosen centroids. Thus, the result of the algorithm depends on
the number of clusters (in DBSCAN, the maximum distance between the two data points
in the same neighborhood should be determined) and the number of runs.
Another challenge comes from the high dimensionality of data, known as “curse of
dimensionality”. Identifying the accurate clusters of data points based on the measured
distances between the pairs of data points may fail since those data points become more
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similar when they are represented in a higher dimensional space [12, 22]. One approach
to deal with the curse of high dimensionality is projecting data into a lower dimensional
space, known as dimensionally reduction. In this approach, the data is represented in
a lower dimensional space while the characteristic(s) (e.g similarities between the data
points) of the original data is preserved. Several methods have used different techniques
based on this concept (e.g. principal component analysis) to determine the cell types [19,
37, 162, 208, 240]. Another approach to deal with this challenge is feature selection, i.e.
eliminating some of the features (genes) that are not informative [96]. In the following,
we provide a brief overview of the related methods that identify the cell types based on
the combination of approaches described above.
Methods SC3 [139] and Seurat [162] use a combination of feature selection, dimensionality reduction, and clustering algorithms to identify the cell types. Authors of SC3
use a consensus clustering framework that combines clustering solutions obtained by the
spectral transformations and k-means clustering based on the complete-linkage hierarchical clustering. They first apply a gene filtering approach on the single-cell gene expression data to remove rare and ubiquitous genes/transcripts. Next, they compute the distance matrices (distance between the cells) using the Euclidean, Pearson, and Spearman
metrics. They transform the distance matrices using either principal component analysis
(PCA) [121], or by computing the eigenvectors of the associated graph Laplacian. Next,
they perform a k-means clustering on the first d eigenvectors of the transformed distance
matrices. Using the different k-means clustering results, they construct a consensus matrix
that represents how often each pair of cells is clustered together. This consensus matrix is
used as an input to a hierarchical clustering using a complete linkage and agglomeration

62
strategies [70]. The clusters are inferred at the k-th level of hierarchy, where k is computed based on the Random Matrix Theory [201, 264]. The accuracy of SC3 is sensitive
to the number of eigenvectors (d), chosen for the spectral transformation. The authors
report that SC3 performs well when d is between 4% and 7% of the number of cells. The
main advantage of SC3 is its high accuracy in identification of cell types. However, it is not
scalable [138].
Seurat [162] is a graph-based clustering method that projects the single cell expression data into the two-dimensional space using the t-distributed stochastic neighbor embedding (t-SNE) technique [161]. Then, it performs the DBSCAN method [78] on the
dimensionality-reduced single cell data. Seurat may fail to find the cell types in small
datasets (low cell numbers) [139]. It is reported that this may be due to possible difficulties in estimating the densities when the number of data points is low.
RaceID [93] determines the cell types by performing a k-means clustering algorithm.
In this method, the gap statistics is used to choose the number of clusters. RaceID does
not perform well when the data does not contain rare cell populations but it appears to be
the preferred methods when the aim is identification of rare types [12, 138, 151, 154].
SNN-Cliq [291] uses the shared nearest neighbor (SNN) concept, which considers the
effect of the surrounding neighbor data points, to handle the high-dimensional data. The
authors of SNN-Cliq compute the similarity between the pairs of data points (the similarity matrix) based on the Euclidean distance, referred as the primary similarity measure.
Using the similarity matrix, they list the k-nearest neighbors (KNN) to each data point.
They propose a secondary similarity measure that computes the similarity between two
data points based on their shared neighborhoods. Consequently, an SNN graph is con-
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structed based on the connectivity between the data points. Then, a graph-based clustering method is applied on the SNN graph in which nodes and weighted edges represent
the data points and similarities between the data points, respectively. The main disadvantage of the graph-based methods such as SNN-Cliq is that scRNASeq data is not inherently
graph-structured [12]. Therefore, the accuracy of these methods depends on the graph
representation of scRNASeq data.
SINCERA [95] performs a hierarchical clustering on the similarity matrix that is computed using the centered Pearson’s correlation. The average linkage approach is used as the
default choice for the linkage. Consensus clustering [181, 286], tight clustering [268] and
ward linkage [283] are provided as alternative clustering approaches. Users can choose a
distance threshold or the number of clusters during the visual inspection when the hierarchical clustering is used for the cell cluster identification. SINCERA tends to identify many
clusters which likely represent the same cell type [12].
One way to identify robust clusters of cells is to resample the cells/genes and compare
the original clusters with the ones that are obtained by resampling [124]. In this thesis,
in order to explore the strength of a pattern (cluster of cells) in the data, we analyze the
sensitivity of that pattern against small changes in the data. The data is resampled by
replacing a certain number of data points with the noise points from a noise distribution.
Our hypothesis is that if there is a strong pattern in data, it will remain despite small perturbations [73]. Here, we develop a stable subtyping (clustering) method that employs
the t-distributed stochastic neighbor embedding (t-SNE) [161] and k-means clustering to
identify the cell types. We add noise and apply a bootstrap method [100, 101] to identify the stable clusters of cells. We use the Adjusted Rand Index (ARI) [113], adjusted
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mutual information (AMI) [274, 275], and V-measure [226] to evaluate the performance
of the clustering result for datasets in which the true cell types are known. We compare
the results of our method [206] with five other methods: RaceID [93], SC3 [139], SEURAT [162], SINCERA [95], and SNN-Cliq [291] using 8 real datasets with known cell types
and 5 simulated datasets. The results of the different methods show that the proposed
method performs better than the five methods across different datasets.
3.3

Data source
The goal of the proposed method is to identify the cell types present in a mixture of

single cells. The input of the method is the single cell gene expression matrix (Mgene×cell )
in which rows represent the genes and columns represent the cells. In the following we
provide more detail about the input data and different steps of the proposed framework.
The overall approach is shown in Figure 12.
The eight publicly available scRNA-seq datasets as well as the five simulation datasets
were used in our analysis.
The list of eight single cell datasets we used in our analysis is summarized in Table 25. We obtained the processed data from Hemberg lab’s website (https://hemberglab.github.io/scRNA.seq.datasets). Hemberg et al. [140] use the SingleCellExperiment
Bioconductor S4 class [158] to store the data, and the scater package [172] for the quality
control and plotting purposes. The normalized data is deposited as a SingleCellExperiment
object (.RData file) and the cell type information is accessed in the cell_type1 column of
the "colData" slot of this object. The gene expression values of the cells are organized as a
matrix in which rows are cells and columns are the genes. In our analysis, genes (features)
that are not expressed in any cells are removed. We did not filter any cell in this analysis.
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We simulated four scRNA-seq datasets with varying degree of cluster separability using
the splatter R package [307].The dataset sim3, consists of 3 subpopulations (1000 cells)
with relative abundances 0.35, 0.30, and 0.35. The dataset sim4 includes 4 subpopulations (3000 cells) with relative abundances 0.15, 0.3, 0.2, and 0.35. The dataset sim6
includes 6 subpopulations (1000 cells) with relative abundances 0.3, 0.1, 0.1, 0.2, 0.2,
and 0.1. Finally, the dataset sim8 consists of 8 subpopulations (2000 cells) with relative
abundances 0.05, 0.1,0.1, 0.2, 0.2, 0.1, 0.15, and 0.1. We also used SPARSim R package [21] to generate a simulation dataset with 8 subpopulations (564 cells) from the real
dataset Tung [269]. Among the eight real datasets, all but three (Klein [142], Patel [200],
Treutlein [267]) are considered as ’gold standard’ since the labels of the cells are known in
a definitive way. Patel [200] and Treutlein [267] are referred as ’silver standard’ by Kiselev
et al. [139] since their cell labels are determined based on the computational methods and
the authors’ knowledge of the underlying biology.
Table 25: Single cell datasets. All the datasets, except Klein, Patel, and Treutlein are
considered as “gold standard”. In the “gold standard” datasets, the cell types are clearly
known. Klein, Patel, and Treutlein are referred as “silver standard’ by [139] since the cell
types are determined based on the computational methods and the authors’ knowledge of
the underlying biology.
Dataset
Biase
Deng
Goolam
Klein
Patel
Pollen
Treutlein
Yan

# cell type
3
10
5
4
5
11
5
8

Organism
Mouse
Mouse
Mouse
Mouse
Human
Human
Mouse
Human

#cell
49
268
124
2717
430
301
80
124

Source
Embryo development
Embryo development
Embryo development
Embryo Stem Cells
Tissues
Tissues
Tissues
Embryo development

Reference
[28]
[65]
[87]
[142]
[200]
[210]
[267]
[296]
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3.4

Proposed framework
One way to identify robust clusters of cells is to resample the cells/genes and compare

the original clusters with the ones that are obtained by resampling [124]. In the current
thesis, in order to explore the strength of a pattern (cluster of cells) in the data, we analyze
the sensitivity of that pattern against small changes in the data. The data is resampled by
replacing a certain number of data points with the noise points from a noise distribution.
Our hypothesis is that if there is a strong pattern in data, it will remain despite small
perturbations [73]. Here, we develop a stable subtyping (clustering) method that employs
the t-distributed stochastic neighbor embedding (tSNE) [161] and k-means clustering to
identify the cell types. We add noise and apply a bootstrap method [100, 101] to identify
the stable clusters of cells. We use the Adjusted Rand Index (ARI) [113] to evaluate the
performance of the clustering result for datasets in which the true cell types are known. We
compare the results of our method with five other methods: RaceID [93], SNN-Cliq [291],
SINCERA [95], SEURAT [162], and SC3 [139] using eight datasets with known cell types.
The ARIs computed on the results of the different methods show that the proposed method
performs better than the five methods across different datasets.
3.4.1

Gene filtering

As shown in Figure 12A, we remove the genes/transcripts that are not expressed in
any cell (expression value is zero in all cells). Such genes cannot provide useful information that can differentiate between cell types [11]. The result of performing the filtering
method on the single cell gene expression matrix (Mgene×cell ) is used as the input to the
second module of the proposed framework.
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Figure 12: The overall workflow of the proposed method for the single cell identification [206]. Given the single cell gene expression matrix, module (A) eliminates the genes
that are not expressed in any cell. Using the resulting matrix, module (B) computes the
Euclidean distance between the cells. The output of this module is a distance matrix in
which the rows and columns are the cells (Dcell×cell ). Module (C) reduces the dimensionality of the distance matrix using the t-distributed stochastic neighbor embedding (t-SNE)
technique. In this module, an average silhouette method is employed to choose the optimal number of clusters k. Finally in module (D), the lower-dimension distance matrix and
the optimal number of clusters k obtained from module (C) are used as the input data to
identify the most stable clustering of cells. Figure 13 shows the details of module D.
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3.4.2

Measuring the dissimilarity between the cells

The distance between the cells is calculated using the Euclidean metric (Figure 12B).
The output of this step is the distance (dissimilarity) matrix Dcell×cell . We reduce the dimension of D by performing the t-distributed stochastic neighbor embedding (t-SNE) [10,
161], the nonlinear dimensionality reduction/visualization technique (Figure 12C). We
0
will refer to the output as Dcell×l
, where 2 ≤ l ≤ cell. In this study, the number of dimen-

sions is 2.
3.4.3

Identification of the optimal number of clusters

This section describes the third module of the proposed method (Figure 12C). In this
analysis, the t-SNE is repeatedly (n=50) applied on the distance matrix Dcell×cell to obtain
0
the dimensionality-reduced distance matrix Dcell×l
. Each time, the optimal number of

clusters is calculated based on the average silhouette method using the dimensionality
reduced distance matrix D0 . In order to find the optimal number of clusters k, the k-means
clustering is applied on the D0 matrix using a range value (default= 2:20), and the k that
maximizes the average silhouette measure is selected. Finally, the average of the selected
numbers k across different repeats (n = 50) (rounded to the nearest integer) is considered
as the final optimal number of clusters.
The silhouette evaluates the quality of that clustering based on how well its data points
are clustered. A silhouette measure is assigned to each data point representing how close
a data point is to its own cluster in comparison to other clusters. For each data point i, this
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measure is calculated as follows:

s(i) =

b(i) − a(i)
max{a(i), b(i)}

where a(i) is the average distance between the data point i and all other data points within
the same cluster. b(i) is the smallest average distance of i to all points in any other cluster
of which i is not a member. s(i) takes values from −1 to 1, where a high positive score
shows that the given data point is well clustered (close to other points in its own cluster
and far from points in the other clusters). Conversely, a high negative score shows that
data point is poorly clustered.
3.4.4

K-means clustering based on the resampling method

This section describes the detail of the last module of the proposed method. As shown
in Figure 13, using the dimensionality reduced distance matrix D0 and the chosen number
of clusters k from the previous step, we identify the most stable clustering by generating
different clustering solutions (clusteringi (i ∈ [1..n])) and measure the stability of each
clustering solution based on a resampling method. The stability measure assigned to each
particular clustering (denoted as clusteringi ) represents how often the k clusters belonging to that clustering are preserved when the input data (D0 ) is resampled several times.
The resampled datasets are generated from D0 by randomly replacing 5% of data points
(cells) with noise. These noisy datasets are then used as the input to k-means algorithm.
Hence, several clusterings (clusteringi,j , j ∈ [1..m]) are generated from the resampled data
(resampled versions of clusteringi ).
In order to assess the stability of each cluster c in the clusteringi (original clustering),
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Figure 13: Identifying the most stable clustering. In this analysis, given the lower0
dimension distance matrix Dcell×l
and the optimal number of clusters k, we calculate n
different clusterings (clustering1 , ..., clusteringn ) using the k-means clustering algorithm.
Then, the stability of each clustering is assessed based on a resampling approach (grey
box). A stability score is assigned to each clustering based on how often its clusters are
recovered when the input data is perturbed (resampled). A clustering with the maximum
stability score is selected as the final solution.
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Figure 14: The resampling framework to compute the stability measure for each clustering.
The input includes N data points X = {x1 , ..., xN }, the number of clusters k , the number
of resamplings m , and the clustering C that is obtained by applying k-means on X. This
analysis generates m resampling data by randomly replacing 5% of data points with the
noise, and computes m resampled clusterings based on k-means clustering. Each cluster c
in C is compared with the most similar cluster in the resampling clustering, and the Jaccard
coefficient between the two clusters is computed, while the noise points are excluded. The
percentage of the times that Jaccard coefficients are larger than 0.75 is considered the
stability measure for cluster c. The average of stability measures for all clusters belonging
to clustering C is calculated and considered as the overall stability measure for clustering
C.
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the cluster c is compared to all the clusters in the clustering that is obtained from the
resample data (clusteringi,j ) based on the Jaccard distance. The Jaccard coefficient [117],
a similarity measure between sets, is used to compute the similarity between two clusters as
follows:
J(A, B) =

|A ∩ B|
,
|A ∪ B|

A, B ⊆ X

where the term A and B are two clusters, consisting of some data points in X = {x1 , · · · , xN }.
If the Jaccard similarity between the cluster c (from the original clustering clusteringi )
and the most similar cluster in the resampled clustering is equal or greater than 0.75, that
cluster is considered stable (preserved). Thus, the stability of each cluster in clusteringi
is calculated as the percentage of the times that cluster is preserved (Jaccard coefficient
≥ 0.75) across the m different resamplings.
We then average the stability measures of the k clusters belonging to clusteringi , and
consider it as the overall stability measure of clusteringi . Among n different clustering
solutions (clusteringi (i ∈ [1..n])), we select the clustering solution with the maximum
stability measure as the final clustering solution.
Figure 14 shows the detail of the resampling method we performed to compute the
stability measure for each clustering. The clusters that are obtained by applying k-mean
on the resampled dataset are compared with the clusters from the original input data only
based on the non-noise points (the noise data points are excluded when two clusters are
compared based on the Jaccard similarity metric.
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3.4.5

Validation methods

We use 13 different datasets in which the cell types (labels) are known. To measure the
level of similarity between the reference labels and the inferred labels that are obtained
by each clustering method, we use three different metrics: adjusted rand index (ARI),
adjusted mutual information (AMI), and V-measure as explained in the following.
Adjusted Rand Index
Given the cell labels, the Adjusted Rand Index (ARI) [113] is used to assess the similarity between the inferred clustering and the true clustering. ARI ranges from 0, for poor
matching (a random clustering), to 1 for a perfect agreement with the true clustering. For
a set of n data points, the contingency table is constructed based on the shared number
of data points between two clusters. Suppose X and Y represent two different clusterings
(representing the row and column of the contingency table, respectively) of n data points .
Xi and Yj denote a cluster in clusterings X and Y , and i and j refer to the row number and
the column number of the contingency table, respectively. The ARI is defined as follow:
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where nij denotes the number of shared data points between clusters Xi and Yj , and
ai =

P

k

nik (the sum of the ith row), and bj =

P

k

nkj (the sum of the j th column of the

contingency table).
Adjusted Mutual Information
The adjusted mutual information (AMI) [274, 275] is a variation of mutual information
that corrects for random partitioning, similar to the way the ARI corrects the rand index.
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As explained in the previous section, given two different clusterings X = {X1 , X2 , ..., XR }
and Y = {Y1 , Y2 , ..., YC } of n data points with R and C clusters, respectively, the mutual
information of cluster overlap between X and Y can be summarized as a contingency table
MR×C = [nij ], where i = 1...R, j = 1...C, and nij represents the number of common data
points between clusters Xi and Yj . Suppose a data point is picked at random from X,
the probability that the data point falls into cluster Xi is p(i) =

|Xi |
.
n

The entropy [245]

associated with the clustering X is calculated as follows:

H(X) =

R
X

P (i) logP (i)

(3.2)

i=1

H(X) is non-negative and takes the value 0 only when there is no uncertainty determining a data point’s cluster membership (there is only one cluster). The mutual information
(M I) between two clusterings X and Y is calculated as follows:

M I(X, Y ) =

R X
C
X

P (i, j) log

i=1 j=1

P (i, j)
P (i)P (j)

(3.3)

where P (i, j) denotes the probability that a data point belongs to both the cluster Xi in X
and the cluster Yj in Y :

P (i, j) =

|Xi ∩ Yj |
n

(3.4)

M I is a non-negative quantity upper bounded by the entropies H(X) and H(Y). It quantifies the information shared by the two clusterings and therefore can be considered as a
clustering similarity measure. The adjusted measure for the mutual information is defined
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as follows:
AM I(X, Y ) =

M I(X, Y ) − E{M I(X, Y )}
max{H(X), H(Y )} − E{M I(X, Y )}

(3.5)

where the expected mutual information between two random clusterings is:

E{M I(X, Y )} =

R X
C
X
i=1 j=1

min(ai ,bj )

X
nij =max(1,ai +bj −n)

nij
n.nij
ai !bj !(n − ai )!(n − bj )!
log(
)
(3.6)
n
ai bj n!nij !(ai − nij )!(bj − nij )!(n − ai − bj + nij )!

where the ai and bj are the partial sums of the contingency table: ai =
bj =

PR

i=1

PC

j=1

nij and

nij .

The adjusted mutual information (AM I) takes a value of 1 when the two clusterings
are identical and 0 when the M I between two partitions equals the value expected due to
chance alone.
V-measure
The V-measure [226] is the harmonic mean between two measures: homogeneity and
completeness. The homogeneity criteria is satisfied if a clustering assigns only those data
points that are members of a single class (true cluster) to a single cluster. Thus, the class
distribution within each cluster should be skewed to a single class (zero entropy) [226].
To determine how close a given clustering is to this ideal, the conditional entropy of
the class distribution given the identified clustering is computed as H(C | K), where
C = {C1 , C2 , ..., Cl } is a set of classes and K is a clustering K = {K1 , K2 , ..., Km }. In the
perfectly homogeneous case, this value is 0. However, this value is dependent on the size of
the dataset and the distribution of class sizes [226]. Thus, this conditional entropy is nor-
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malized by the maximum reduction in entropy the clustering information could provide,
H(C). Therefore, the homogeneity is defined as follows:

h=





1

if H(C, K) = 0




1- H(C|K)
H(C)

otherwise

(3.7)

The completeness is symmetrical to homogeneity [226]. In order to satisfy the completeness criteria, a clustering must assign all of those data points that are members of a
single class to a single cluster. To measure the completeness, the distribution of cluster assignments within each class is assessed [226]. In a perfectly complete clustering solution,
each of these distributions will be completely skewed to a single cluster.
Given the homogeneity h and completeness c, the V-measure is computed as the weighted
harmonic mean of homogeneity and completeness:

V-measure =

(1 + β) ∗ h ∗ c
(β ∗ h) + c

(3.8)

if β is greater than 1, completeness is weighted more strongly in the calculation [226].
If β is less than 1, homogeneity is weighted more strongly. Since the computations of
homogeneity, completeness and V-measure are completely independent of the number of
classes, the number of clusters, the size of the dataset and the clustering algorithm, these
measures can be employed for evaluating any clustering solution.
3.5

Results and validation
Tables 26–28 shows the comparison between the proposed method and five other meth-

ods: RaceID [93], SC3 [139], SEURAT [162], SINCERA [95], and SNN-Cliq [291] using
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the three metrics: ARI, AMI, and V-measures, respectively.
We used the R package fpc [102] to compute the k-means clustering based on the
resampling method. We generated 20 different clusterings, and for each clustering we
computed 1,000 clusterings based on the resampled datasets to find the most meaningful
clustering. We used the log-transformation (M 0 = log2(M + 1)) for all methods except
SINCERA. For SINCERA we followed the authors instructions [95] and used the original z-score normalization instead of the log-transformation. In order to generate SC3
results, we used the R package SC3 (http://bioconductor.org/packages/SC3, v.1.8.0). We
applied the same gene filtering approach that authors proposed in their study (parameter
gene_filter=TRUE).
For SEURAT we used the Seurat R package (v.2.3.4) [35]. We performed the t-SNE
using the Rtsne R package with the default parameters, and we used DBSCAN algorithm for clustering. We ran SNN-cliq with the default parameters that are provided
by the authors [291]. For RaceID, we used the R code provided by the authors [93]
(https://github.com/dgrun/RaceID).
As shown in Figure 15, the proposed method performs better than the five methods
across 13 different datasets. In this figure, the three boxplots shows the the performance
of each method on these 13 datasets based on the adjusted rand index (ARI), adjusted
mutual information (AMI), and V-measure. We performed the proposed method, SC3 and
RaceID on each dataset for 50, 5, and 50 times, respectively. In these three methods, we
calculated the average of ARIs, AMIs, and V-measures over different runs. Since SC3 is
reported as a stable method by the authors [139], we run it only 5 times. Indeed, we have
observed the results with a very small standard deviation in all 5 runs for all 13 datasets
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Table 26: A comparison between the results of six methods: proposed, RaceID, SC3, Seurat, SINCERA, and SNN-Cliq. The adjusted rand index (ARI) [113] is used to evaluate
the performance of each clustering method. The proposed method, RaceID, and SC3 are
performed 50, 50, and 5 times on each dataset, respectively. SC3 was performed only 5
times because it is very stable (standard deviation of zero for all datasets). The average
ARIs across different runs are computed for the proposed method, SC3, and RaceID. Since
SNN-Cliq, SINCERA and SEURAT are deterministic, they are performed only once. The
proposed method was the best for 8 out of the 13 datasets. The proposed method also
yielded the best average ARI, as shown in Figure 15.
Dataset

#cell types

Biase
3
Deng
10
Goolam
5
Klein
4
Patel
5
Pollen
11
Treutlein
5
Yan
8
sim3
3
sim4
4
sim6
6
sim8
8
sim±Tung 8
Dataset
Biase
Deng
Goolam
Klein
Patel
Pollen
Treutlein
Yan
sim3
sim4
sim6
sim8
sim_Tung

#cell types
3
10
5
4
5
11
5
8
3
4
6
8
8

Proposed
K (mean±sd)
3±0
10±0
3±0
6±0
5±0
8±0
3±0
5±0
3±0
4±0
7.9±0.3
9.34±0.47
8±0

ARI (mean)
0.94±0.01
0.58±0.02
0.8±0.09
0.69±0.01
0.66±0.09
0.86±0.02
0.72±0.03
0.81±0.02
1±0±0
0.99±0.005
0.56±0.03
0.77±0.03
0.42±0

RaceID
K (mean±sd)
3.14±0.6
1
1
2.98±0.14
7.44±1.88
8.36±2.27
1±0
5.5±2.34
1±0
1±0
1±0
1±0
1±0

SC3
ARI (mean) K (mean±sd) ARI (mean±sd)
0.84±0.25
3±0
0.94±0
0±0
9±0
0.65±0
0±0
6±0
0.59±0
0.48±0.001 19±0
0.44±0.01
0.66±0.08
17±0
0.45±0.01
0.55±0.11
10±0
0.93±0
0±0
3±0
0.66±0
0.55±0.17
4±0
0.76±0
0±0
3±0
1±0
0±0
4±0
0.99±0.0005
0±0
3±0
0.53±0
0±0
4±0
0.53±0.04
0±0
8±0
0±0

SINCERA
K
6
3
13
43
10
10
7
8
120
464
68
68
17

ARI
0.71
0.42
0.19
0.45
0.78
0.9
0.35
0.59
0.12
0.08
0.25
0.35
0.001

SNN-Cliq
K
6
17
17
265
26
22
5
13
147
437
143
290
77

ARI
0.66
0.4
0.2
0.11
0.14
0.71
0.62
0.79
0.03
0.01
0.06
0.05
0.001

Seurat
K
4
6
3
3
5
8
1
3
3
3
6
8
8

ARI
0.78
0.45
0.05
0
0.63
0.85
0
0.56
1
0.57
1
1
0

confirming the claims of the authors. The other clustering methods SEURAT, SINCERA,
and SNN-Cliq were run only once since they are deterministic.
3.6

Discussion
The results shown in Tables 26–28 merit some discussion. The Goolam dataset, for

instance, includes 5 true cell types. On this dataset, the proposed algorithm identifies 3
clusters, while SC3 identifies 6, RaceID 1, Seurat 2, SINCERA 13 and SNN-Cliq 17 types.
Even though the number of clusters closest to the number of true types is 6, as yielded by
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Table 27: A comparison between the results of six methods: proposed, RaceID, SC3, Seurat, SINCERA, and SNN-Cliq.The adjusted mutual information (AMI) [274, 275], is used
to evaluate the performance of each clustering method. The proposed method, RaceID,
and SC3 are performed 50, 50, and 5 times on each dataset, respectively. The average
AMIs across different runs are computed for the proposed method, SC3, and RaceID. Since
SNN-Cliq, SINCERA and SEURAT are deterministic, they are performed only once.
Dataset

#cell types

Biase
Deng
Goolam
Klein
Patel
Pollen
Treutlein
Yan
sim3
sim4
sim6
sim8
sim_Tung

3
10
5
4
5
11
5
8
3
4
6
8
8

Dataset

#cell types

Biase
Deng
Goolam
Klein
Patel
Pollen
Treutlein
Yan
sim3
sim4
sim6
sim8
sim_Tung

3
10
5
4
5
11
5
8
3
4
6
8
8

Proposed
K (mean±sd)
3±0
10±0
3±0
6±0
5±0
8±0
3±0
5±0
3±0
4±0
7.9±0.3
9.34±0.47
8±0

AMI (mean±sd)
0.92±0.02
0.73±0.01
0.73±0.04
0.67±0.06
0.86±0.01
0.72±0.01
0.54±0.03
0.78±0.01
1±0
0.99±0.007
0.64±0.02
0.85±0.01
0.51±0.008

RaceID
K (mean±sd) K (mean±sd)
3.14±0.6
0.85±0.23
1±0
0±0
1±0
0±0
2.98±0.14
0.51±0.05
7.44±1.88
0.66±0.1
8.36±2.27
0.68±0
1±0
0±0
5.5±2.34
0.61±0.17
1±0
0±0
1±0
0±0
1±0
0±0
1±0
0±0
1±0
0±0

SC3
K (mean±sd)
3±0
9±0
6±0
19±0
17±0
10±0
3±0
4±0
3±0
4±0
3±0
4±0
8±0

AMI (mean±sd)
0.92±0
0.81±0
0.69±0
0.53±0
0.93±0
0.53±0.01
0.62±0
0.72±0
1±0
0.99±0.001
0.51±0
0.56±0
0.006±0

SINCERA
K
6
3
13
43
10
10
7
8
120
464
68
68
17

AMI
0.64
0.48
0.4
0.52
0.73
0.91
0.46
0.72
0.23
0.21
0.42
0.51
0.04

SNN-Cliq
K
6
17
17
265
26
22
5
13
147
437
143
290
77

Seurat
K
4
6
3
3
5
8
1
3
3
3
6
8
8

AMI
0.74
0.59
0.11
0.06
0.68
0.87
0
0.58
1
0.66
1
1
0

AMI
0.62
0.6
0.42
0.21
0.31
0.74
0.51
0.76
0.21
0.2
0.3
0.31
0.13

SC3, the membership of various cells in these clusters is not correct since the ARI index
associated to these 6 clusters is only 0.59 compared to the ARI index of 0.8 associated to
the 3 clusters constructed by the proposed method.
Conversely, for the Patel dataset that includes 5 cell types, the proposed method was
able to correctly estimate the number of clusters (k=5). However, the distribution of the
individual cells across these five clusters is not perfect, as illustrated by the lower ARI value
of 0.66, compared to the 0.78 ARI associated with the SINCERA results.
As another observation, the Pollen dataset includes 11 cell types. Using this dataset, the
number of clusters (k=10) determined by SINCERA is close to the correct number of cell
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Table 28: A comparison between the results of six methods: proposed, RaceID, SC3, Seurat, SINCERA, and SNN-Cliq. The V-measure [226] is used to evaluate the performance of
each clustering method. The proposed method, RaceID, and SC3 are performed 50, 50,
and 5 times on each dataset, respectively. The average V-measures across different runs
are computed for the proposed method, SC3, and RaceID. Since SNN-Cliq, SINCERA and
SEURAT are deterministic, they are performed only once.
Dataset

#cell types Proposed
K (mean±sd)
Biase
3
3±0
Deng
10
10±0
Goolam
5
3±0
Klein
4
6±0
Patel
5
5±0
Pollen
11
8±0
Treutlein 5
3±0
Yan
8
5±0
sim3
3
3±0
sim4
4
4±0
sim6
6
7.9±0.3
sim8
8
9.34±0.47
sim_Tung 8
8±0
Dataset
Biase
Deng
Goolam
Klein
Patel
Pollen
Treutlein
Yan
sim3
sim4
sim6
sim8
sim_Tung

#cell types SINCERA
K
3
6
10
3
5
13
4
43
5
10
11
10
5
7
8
8
3
120
4
464
6
68
8
68
8
17

V-measure (mean)
0.93±0.03
0.72±0.01
0.82±0.04
0.38±0.01
0.56±0.02
0.95±0.01
0.96±0
0.83±0.02
1±0
0.99±0.0002
0.98±0
0.99±0
0.96±0.03

RaceID
K (mean±sd) V-measure (mean)
3.14±0.6
0.87±0.2
1±0
0±0
1±0
0±0
2.98±0.14
0.4±0.06
7.44±1.88
0.54±0.04
8.36±2.27
0.76±0.03
1±0
0±0
5.5±2.34
0.68±0.07
1±0
0±0
1±0
0±0
1±0
0±0
1±0
0±0
1±0
0±0

SC3
K (mean±sd)
3
9
6
19
17
10
3
4
3
4
3
4
8

V-measure (mean)
0.93±0
0.74±0.001
0.98±0
0.31±0.002
0.46±0.002
0.93±0
0.89±0
0.81±0
1±0
0.99±0.00003
0.97±0.0004
0.98±0.004
0.66±0

V-measure
0.72
0.93
0.71
0.36
0.55
0.94
0.93
0.65
0.95
0.97
0.97
0.98
0.82

SNN-Cliq
K
6
17
17
265
26
22
5
13
147
437
143
290
77

Seurat
K
4
6
3
3
5
8
1
3
3
3
6
8
8

V-measure
0.73
0.93
0.66
0.46
0.62
0.93
0
0.73
1
0.96
1
1
0.66

V-measure
0.7
0.64
0.65
0.29
0.44
0.72
0.92
0.78
0.95
0.97
0.97
0.98
0.8

types. However, SC3 achieved better clustering (ARI=0.93) in contrast to the five other
methods. SC3 identified 17 different clusters using this dataset.
Two conclusions may be drawn from these observations. First, results should not be
assessed based on the agreement between the number of clusters found and the number of
known cell types – the assignment of each cell to a given type is more important. Second,
larger number of clusters reported will be associated with larger values of ARI. Therefore,
results that include very large number of clusters should be regarded with caution.
RaceID and Seurat both were not able to find a meaningful clustering for the Treutlein
dataset. The identified number of clusters by both RaceID and Seurat is 1 (k=1), while
this dataset includes 5 different cell types. As a result, the clusterings obtained by these

81

RaceID

SC3

Seurat

SINCERA

SNN−Cliq

RaceID

SC3

Seurat

SINCERA

SNN−Cliq

0.2
0.0
SNN−Cliq

Proposed
Proposed

0.0

0.4

SINCERA

0.2

0.6

Seurat

0.4

0.8

SC3

0.6

1.0

RaceID

0.8

Proposed

Adjusted Mutual Information

Adjusted Rand Index

1.0

1.0

V−measure

0.8
0.6
0.4
0.2
0.0

Figure 15: The performance comparison using 13 single cell datasets based on three metrics: the adjusted rand index (ARI), adjusted mutual information (AMI), and V-measure.
The proposed method and RaceID were applied 50 times on each dataset. SC3 was used
only 5 times on each dataset because it is very stable. The average ARIs, AMIs, and Vmeasures across different runs are computed for the proposed method, RaceID, and SC3.
Since SNN-Cliq, SINCERA, and SEURAT are deterministic, they are run only once for each
dataset.
two methods are poorly matched to the reference clustering. In Deng dataset, the best ARI
of 0.65 is obtained by SC3 but this value is not very high. The poor results obtained by all
6 methods using this dataset might be due to noisy data.
We also assessed the reproducibility/stability of the stochastic methods: proposed [206],
RaceID, and SC3 by running each method several times. Although SC3’s consensus pipeline
provides a very stable solution (very low standard deviation for the three metrics and k
across all datasets), it is computationally more costly than other methods. In summary,
one key advantage of our proposed method is that we produce consistent clustering across
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Biase

0
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Figure 16: The run time of the different methods using 13 single cell datasets.
different datasets.
The run time for each method using 13 different datasets is shown in Figure 16. It
is notable that RaceID, the proposed method, and SC3 have a non-linear increase in run
time. At this time, it appears that it is unfeasible to perform this method on large datasets
consisting of thousands of cells. The fastest method among all the methods is Seurat, which
is a graph-based method. The graph-based methods often return only a single clustering
solution with a faster run time and they do not require the user to provide the number of
clusters [138]. Seurat is a popular choice for the large data sets based on the its optimal
speed and scalability. However, it has been shown that Seurat does not provide an accurate
solution for smaller datasets [138]. The details of the run times are shown in Table 29.
More generally, finding an optimal clustering method that provides stable solutions for
all situations may not be possible. In fact, because no method can perform well for all
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Table 29: The run time (secs) of the different methods using 13 single cell datasets, including 5 simulation datasets.

Biase
Deng
Goolam
Klein
patel
Pollen
treutlein
Yan
sim3
sim4
sim6
sim8
sim_Tung

Proposed
43.47
188.51
86.55
3709.28
154.18
257.14
53.49
87.74
777.08
3381.1
510.48
1839.75
504.6

RaceID
SC3
Seurat
8.79
59.79
27.3
55.37
234.3
23.68
15.69
59.52
41.36
16175.58 6127.56 117.1
100.32
933.05
13.78
50.5
245.02
25.86
8.34
47.89
23.09
13.46
60.31
19.5
1102.2
3888
63
38232
8532
85.2
670.2
4716
31.09
10160.64 1733.4
53.33
171.6
458.4
40.66

SINCERA
3.56
10
14.16
952.25
10.25
13.11
5.82
4.96
118.8
170.4
18.3
85.2
37.36

SNN-Cliq
0.62
16.39
5.75
4643.8
12.22
17.35
1.33
2.23
84.71
439.12
23.01
157.47
86.13

situations, a comparative analysis of methods based on a set of criteria should be employed [138].
In the following, we investigate the application of the uniform manifold approximation
and projection (UMAP) for reducing the dimensionality of the single cell data that is used
for the resampling-based clustering framework. We also provide the performance of the
clustering results using different noise tuning hyperparmaters.
3.6.1

Uniform manifold approximation and projection

We investigated the performance of the resampling-based k-means clustering method
using two dimensionality reduction techniques: the t-distributed stochastic neighbor embedding (t-SNE) and Uniform Manifold Approximation and Projection (UMAP).
The UMAP is an algorithm for reducing the dimensionality of the data based on manifold learning techniques and the topological data analysis. Unlike t-SNE [161] that preserves only local structure in the data, UMAP [174] claims to preserve both local and the
global structure in the data. The main difference between t-SNE and UMAP is the inter-
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pretation of the distance between objects or clusters [174].

0.8
0.7
0.6
0.5
0.4

t−SNE

UMAP

t−SNE

UMAP

0.3

1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
UMAP

0.9

t−SNE

Adjusted Mutual Information

Adjusted Rand Index

1.0

1.0

V−measure

0.9
0.8
0.7
0.6
0.5
0.4

Figure 17: In this comparison, 13 datasets, including 8 real single cell gene expression
datasets are used. The results are compared based on the three metrics: the adjusted rand
index (ARI), adjusted mutual information (AMI), and V-measure. The results show that
the t-SNE dimensionality reduction technique provides better performance in comparison
to the UMAP technique.

We applied the UMAP [174] to reduce the dimensionality of the distance matrix in
which the rows and columns are the cells. Then, we identified the most stable clustering
of cells using the lower-dimension distance matrix based on the resampled-based k-means
clustering. As shown in Figure 17, we found that the performance is better when t-SNE is
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used for the dimensionality reduction.
Tables 30–32 show the comparison between the results of six methods: K-means-UMAP,
RaceID, SC3, Seurat, SINCERA, and SNN-Cliq .The K-means-UMAP is an alternative to the
proposed method in which UMAP technique is employed for the dimensionality reduction.
Table 30: A comparison between the results of six methods: K-means-UMAP, RaceID, SC3,
Seurat, SINCERA, and SNN-Cliq based on the adjusted rand index (ARI). The K-meansUMAP is an alternative to the proposed method in which UMAP technique is employed
for the dimensionality reduction. The K-means-UMAP method, RaceID, and SC3 are performed 50, 50, and 5 times on each dataset, respectively. SC3 was performed only 5 times
because it is very stable (standard deviation of zero for all datasets). The average ARIs
across different runs are computed for the K-means-UMAP, SC3, and RaceID. Since SNNCliq, SINCERA and SEURAT are deterministic, they are performed only once. For each
dataset, the best ARI is highlighted in green.
Dataset

#cell types

K-means-UMAP
K (mean±sd) ARI (mean±sd)

RaceID
SC3
K (mean±sd) ARI (mean±sd) K (mean±sd) ARI (mean±sd)

SINCERA
K
ARI

SNN-Cliq
K
ARI

Biase
Deng
Goolam
Klein
Patel
Pollen
Treutlein
Yan
sim3
sim4
sim6
sim8
sim_Tung

3
10
5
4
5
11
5
8
3
4
6
8
8

3±0
5±0
2.88±0.33
3±0
2.76±0.52
7.98±0.14
3.24±0.43
8±0
3±0
3±0
16.72±0.45
18±0
8±0

3.14±0.6
1±0
1±0
2.98±0.14
7.44±1.88
8.36±2.27
1±0
5.5±2.34
1±0
1±0
1±0
1±0
1±0

6
0.71
3
0.42
13
0.19
43
0.45
10
0.78
10
0.9
7
0.35
8
0.59
120 0.12
464 0.08
68
0.25
68
0.35
17
0.001

6
17
17
265
26
22
5
13
147
437
143
290
77

0.95±0
0.39±0.02
0.82±0.11
0.55±0
0.31±0.07
0.84±0.03
0.51±0.12
0.75±0.1
0.99±0.01
0.55±0
0.32±0.02
0.38±0.02
0.41±0.01

0.84±0.25
0±0
0±0
0.48±0.001
0.66±0.08
0.55±0.11
0±0
0.55±0.17
0±0
0±0
0±0
0±0
0±0

3±0
9±0
6±0
19±0
17±0
10±0
3±0
4±0
3±0
4±0
3±0
4±0
8±0

0.94±0
0.65±0.002
0.59±0
0.44±0.01
0.45±0.01
0.93±0
0.66±0
0.76±0
1±0
0.99±0.0005
0.53±0.005
0.53±0.04
0±0

Seurat
K ARI

0.66
4
0.4
6
0.2
3
0.11
3
0.14
5
0.71
8
0.62
1
0.79
3
0.03
3
0.01
3
0.06
6
0.05
8
0.001 8

0.78
0.45
0.05
0
0.63
0.85
0
0.56
1
0.57
1
1
0

Table 31: A comparison between the results of six methods: K-means-UMAP, RaceID,
SC3, Seurat, SINCERA, and SNN-Cliq based on the adjusted mutual information (AMI).
The K-means-UMAP is an alternative to the proposed method in which UMAP technique
is employed for the dimensionality reduction. The K-means-UMAP, RaceID, and SC3 are
performed 50, 50, and 5 times on each dataset, respectively. The average AMIs across
different runs are computed for the K-means-UMAP, SC3, and RaceID. Since SNN-Cliq,
SINCERA and SEURAT are deterministic, they are performed only once.
Dataset

#cell types

K-means-UMAP
RaceID
K (mean±sd) AMI (mean±sd) K (mean±sd) AMI (mean±sd)

SC3
K (mean±sd) AMI (mean±sd)

SINCERA
K
AMI

SNN-Cliq
K
AMI

Seurat
K AMI

Biase
Deng
Goolam
Klein
Patel
Pollen
Treutlein
Yan
sim3
sim4
sim6
sim8
sim_Tung

3
10
5
4
5
11
5
8
3
4
6
8
8

3±0
5±0
2.88±0.33
3±0
2.76±0.52
7.98±0.14
3.24±0.43
8±0
3±0
4±0
16.72±0.45
18±0
8±0

3±0
9±0
6±0
19±0
17±0
10±0
3±0
4±0
3±0
4±0
3±0
4±0
8±0

6
3
13
43
10
10
7
8
120
464
68
68
17

6
17
17
265
26
22
5
13
147
437
143
290
77

4
6
3
3
5
8
1
3
3
3
6
8
8

0.92±0
0.51±0.01
0.72±0.1
0.53±0
0.31±0.07
0.85±0.02
0.44±0.06
0.80±0.04
0.99±0.02
0.61±0
0.48±0.01
0.53±0.01
0.50±0.01

3.14±0.6
1±0
1±0
2.98±0.14
7.44±1.88
8.36±2.27
1±0
5.5±2.34
1±0
1±0
1±0
1±0
1±0

0.85±0.23
0±0
0±0
0.51±0.05
0.66±0.1
0.68±0
0±0
0.61±0.17
0±0
0±0
0±0
0±0
0±0

0.92±0
0.81±0.006
0.69±0
0.53±0.006
0.93±0
0.53±0.01
0.62±0
0.72±0
1±0
0.99±0.001
0.51±0.004
0.56±0.007
0.006±0

0.64
0.48
0.4
0.52
0.73
0.91
0.46
0.72
0.23
0.21
0.42
0.51
0.04

0.62
0.6
0.42
0.21
0.31
0.74
0.51
0.76
0.21
0.2
0.3
0.31
0.13

0.74
0.59
0.11
0.06
0.68
0.87
0
0.58
1
0.66
1
1
0
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Table 32: A comparison between the results of six methods: K-means-UMAP, RaceID,
SC3, Seurat, SINCERA, and SNN-Cliq based on the V-measure. The K-means-UMAP is
an alternative to the proposed method in which UMAP technique is employed for the
dimensionality reduction. The K-means-UMAP, RaceID, and SC3 are performed 50, 50,
and 5 times on each dataset, respectively. The average V-measures across different runs
are computed for the K-means-UMAP, SC3, and RaceID. Since SNN-Cliq, SINCERA and
SEURAT are deterministic, they are performed only once. For each dataset, the best Vmeasure is highlighted in green.
Dataset

#cell types

Biase
3
Deng
10
Goolam
5
Klein
4
Patel
5
Pollen
11
Treutlein 5
Yan
8
sim3
3
sim4
4
sim6
6
sim8
8
sim_Tung 8

3.6.2

K-means-UMAP
RaceID
SC3
SINCERA
SNN-Cliq
K (mean±sd) V-measure (mean±sd) K (mean±sd) V-measure (mean±sd) K (mean±sd) V-measure (mean±sd) K
V-measure K
V-measure
3±0
5±0
2.88±0.33
3±0
2.76±0.52
7.98±0.14
3.24±0.43
8±0
3±0
3±0
16.72±0.45
18±0
8±0

0.93±0
0.75±0.06
0.84±0.04
0.40±0
0.54±0.02
0.94±0.02
0.94±0.01
0.77±0.07
1±0
0.98±0
0.98±0
0.99±0
0.91±0.01

3.14±0.6
1±0
1±0
2.98±0.14
7.44±1.88
8.36±2.27
1±0
5.5±2.34
1±0
1±0
1±0
1±0
1±0

0.87±0.2
0±0
0±0
0.4±0.06
0.54±0.04
0.76±0.03
0±0
0.68±0.07
0±0
0±0
0±0
0±0
0±0

3
9
6
19
17
10
3
4
3
4
3
4
8

0.93±0
0.74±0.001
0.98±0
0.31±0.002
0.46±0.002
0.93±0
0.89±0
0.81±0
1±0
0.99±0.00003
0.97±0.0004
0.98±0.004
0.66±0

6
3
13
43
10
10
7
8
120
464
68
68
17

0.72
0.93
0.71
0.36
0.55
0.94
0.93
0.65
0.95
0.97
0.97
0.98
0.82

6
17
17
265
26
22
5
13
147
437
143
290
77

0.7
0.64
0.65
0.29
0.44
0.72
0.92
0.78
0.95
0.97
0.97
0.98
0.80

K

Seurat
V-measure

4
6
3
3
5
8
1
3
3
3
6
8
8

0.73
0.93
0.66
0.46
0.62
0.93
0
0.73
1
0.96
1
1
0.66

Noise tuning for the resampling-based clustering approach

We replaced the 5% of the data points with noise (noise tuning threshold=0.05).
In [100], Hennig performed a comparative analysis using two thresholds 0.05 and 0.2
and showed that the threshold 0.05 provides more stable clusterings. We assessed the
performance of our proposed method using other noise tuning thresholds: 0.1 and 0.2.
Tables 33–35 show comparison between the proposed method (using 3 thresholds) and
five other methods based on the three metrics: the adjusted rand index (ARI), adjusted
mutual information (AMI), and V-measure. Indeed, we have observed the threshold 0.05
provides better performance.
To assess the stability of a cluster, we used the same threshold (0.75) that is recommended by Hennig [100]. In this study [100], it has been shown that a stable cluster will
yield a Jaccard similarity value of 0.75 or more. Thus, if the Jaccard similarity between the
cluster (from original clustering) and the most similar cluster in the resampled clustering
is equal or greater than 0.75, that the cluster is considered as successfully recovered.
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Table 33: A comparison between the results of six methods: proposed (noise tuning thresholds: 0.05, 0.1 and 0.2), RaceID, SC3, Seurat, SINCERA, and SNN-Cliq. The adjusted rand
index (ARI) [113] is used to evaluate the performance of each clustering method. The
proposed method was performed based on three noise tuning thresholds: 0.05, 0.1 and
0.2. The proposed method, RaceID, and SC3 are performed 50, 50, and 5 times on each
dataset, respectively. SC3 was performed only 5 times because it is very stable (standard
deviation of zero for all datasets). The average ARIs across different runs are computed
for the proposed method, SC3, and RaceID. Since SNN-Cliq, SINCERA and SEURAT are
deterministic, they are performed only once. For each dataset, the best ARI is highlighted
in green.
Dataset

#cell types

Proposed- ARI (mean±sd)
Threshold=0.05 Threshold=0.1 Threshold=0.2

RaceID
ARI (mean±sd)

SC3
ARI (mean±sd)

SINCERA SNN-Cliq Seurat
ARI
ARI
ARI

Biase
Deng
Goolam
Klein
Patel
Pollen
Treutlein
Yan
sim3
sim4
sim6
sim8
sim_Tung

3
10
5
4
5
11
5
8
3
4
6
8
8

0.94±0.01
0.58±0.02
0.80±0.09
0.69±0.01
0.66±0.09
0.86±0.02
0.72±0.03
0.81±0.02
1±0
0.99±0.005
0.56±0.03
0.77±0.03
0.42±0

0.84±0.25
9±0
0±0
0.48±0.001
0.66±0.08
0.55±0.11
0±0
0.55±0.17
0±0
0±0
0±0
0±0
0±0

0.94±0
0.65±0.002
0.59±0
0.44±0.01
0.45±0.01
0.93±0
0.66±0
0.76±0
1±0
0.99±0.0005
0.53±0.005
0.53±0.04
0±0

0.71
0.42
0.19
0.45
0.78
0.90
0.35
0.59
0.12
0.08
0.25
0.35
0.001

0.95±0.01
0.43±0.03
0.75±0.12
0.70±0.01
0.96±0.01
0.89±0.04
0.32±0.04
0.82±0.09
1±0
0.90±0.08
0.59±0.03
0.78±0.04
0±0

0.91±0.15
0.43±0.01
0.69±0.13
0.70±0.03
0.95±0.01
0.85±0.05
0.31±0.04
0.90±0.03
1±0
0.89±0.08
0.56±0.05
0.79±0.045
0±0

0.66
0.4
0.20
0.11
0.14
0.71
0.62
0.79
0.03
0.01
0.06
0.05
0.001

0.78
0.45
0.05
0
0.63
0.85
0
0.56
1
0.57
1
1
0

Table 34: A comparison between the results of six methods: proposed (noise tuning thresholds: 0.05, 0.1 and 0.2), RaceID, SC3, Seurat, SINCERA, and SNN-Cliq. The adjusted mutual information (AMI) [274, 275] is used to evaluate the performance of each clustering
method. The proposed method was performed based on three noise tuning thresholds:
0.05, 0.1 and 0.2. The proposed method, RaceID, and SC3 are performed 50, 50, and 5
times on each dataset, respectively. The average AMIs across different runs are computed
for the proposed method, SC3, and RaceID. Since SNN-Cliq, SINCERA and SEURAT are
deterministic, they are performed only once. For each dataset, the best AMI is highlighted
in green.
Dataset

#cell types

Proposed- AMI (mean±sd)
RaceID
Threshold=0.05 Threshold=0.1 Threshold=0.2 AMI (mean±sd)

SC3
SINCERA SNN-Cliq Seurat
AMI (mean±sd) AMI
AMI
AMI

Biase
Deng
Goolam
Klein
Patel
Pollen
Treutlein
Yan
sim3
sim4
sim6
sim8
sim_Tung

3
10
5
4
5
11
5
8
3
4
6
8
8

0.92±0.02
0.73±0.01
0.73±0.04
0.67±0.06
0.86±0.01
0.72±0.01
0.54±0.03
0.78±0.01
1±0
0.99±0.007
0.64±0.02
0.85±0.01
0.51±0.008

0.92±0
0.81±0.006
0.69±0
0.53±0.006
0.93±0 0
0.53±0.01
0.62±0
0.72±0
1±0
0.99±0.001
0.51±0.004
0.56±0.007
0.006±0

0.88±0.15
0.58±0.03
0.73±0.05
0.73±0.01
0.94±0.03
0.89±0.02
0.41±0.04
0.78±0.01
1±0
0.91±0.07
0.66±0.02
0.85±0.02
0.01±0

0.90±0.07
0.58±0.02
0.71±0.05
0.73±0.02
0.94±0.01
0.88±0.02
0.42±0.04
0.89±0.04
1±0.01
0.89±0.07
0.65±0.03
0.85±0.02
0.01±0

0.85±0.23
0±0
0±0
0.51±0.05
0.66±0.1
0.68±0
0±0
0.61±0.17
0±0
0±0
0±0
0±0
0±0

0.64
0.48
0.4
0.52
0.73
0.91
0.46
0.72
0.23
0.21
0.42
0.51
0.04

0.62
0.6
0.42
0.21
0.31
0.74
0.51
0.76
0.21
0.2
0.3
0.31
0.13

0.74
0.59
0.11
0.06
0.68
0.87
0
0.58
1
0.66
1
1
0
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Table 35: A comparison between the results of six methods: proposed (noise tuning
thresholds: 0.05, 0.1 and 0.2), RaceID, SC3, Seurat, SINCERA, and SNN-Cliq. The Vmeasure [226] is used to evaluate the performance of each clustering method. The proposed method was performed based on three noise tuning thresholds: 0.05, 0.1 and 0.2.
The proposed method, RaceID, and SC3 are performed 50, 50, and 5 times on each dataset,
respectively. The average V-measures across different runs are computed for the proposed
method, SC3, and RaceID. Since SNN-Cliq, SINCERA and SEURAT are deterministic, they
are performed only once. For each dataset, the best V-measure is highlighted in green.
Dataset

#cell types

Proposed- V-measure (mean±sd)
Threshold=0.05 Threshold=0.1 Threshold=0.2

RaceID
SC3
V-measure (mean±sd) V-measure (mean±sd)

SINCERA
V-measure

SNN-Cliq
V-measure

Seurat
V-measure

Biase
Deng
Goolam
Klein
Patel
Pollen
Treutlein
Yan
sim3
sim4
sim6
sim8
sim_Tung

3
10
5
4
5
11
5
8
3
4
6
8
8

0.93±0.03
0.72±0.01
0.82±0.04
0.38±0.01
0.56±0.02
0.95±0.01
0.96±0
0.83±0.02
1±0
0.99±0.0002
0.98±0
0.99±0
0.96±0.03

0.87±0.2
0±0
0±0
0.40±0.02
0.54±0.04
0.76±0.03
0±0
0.68±0.07
0±0
0±0
0.99±0
0±0
0±0

0.72 6
0.93
0.71
0.36
0.55
0.94
0.93
0.65
0.95
0.97
0.97
0.98
0.82

0.7
0.64
0.65
0.29
0.44
0.72
0.92
0.78
0.95
0.97
0.97
0.98
0.80

0.73
0.93
0.66
0.46
0.62
0.93
0
0.73
1
0.96
1
1
0.66

3.7

0.93±0.02
0.75±0.06
0.86±0.09
0.39±0.01
0.81±0.03
0.92±0.02
0.93±0.01
0.85±0.04
1±0
0.99±0.003
0.99±0.001
0.99±0.0009
0.71±0.01

0.90±0.1
0.81±0.1
0.85±0.09
0.40±0.03
0.81±0.03
0.91±0.02
0.93±0.01
0.87±0.04
1±0
0.99±0
0.99±0
1±0
0.71±0.01

0.93±0
0.74±0.001
0.98±0
0.31±0.002
0.46±0.002
0.93±0
0.89±0
0.81±0
1±0
0.99±0.00003
0.99±0.0004
0.98±0.004
0.66±0

Summary
Recent advances in single-cell RNA-Seq (scRNASeq) provide the opportunity to per-

form single-cell transcriptome analysis. In this thesis, we develop a pipeline to cluster the
individual cells based on their gene expression values such that each cluster consisting
of cells with specific functions or distinct developmental stages. We first filter genes that
are not expressed in any cell. Then, we compute the distance between the cells using
the Euclidean distance. We reduce the dimensions of the distance matrix data using the
t-distributed stochastic neighbor embedding (t-SNE) technique. Based on the dimensionality reduced distance matrix, we explore strong patterns (clusters) of cells by randomly
drawing a percentage of the data points without replacement, and replacing them with
points from a noise distribution. We apply the proposed method on 13 different single cell
datasets, and we compare it with five related methods: RaceID, SC3, Seurat, SINCERA,
and SNN-Cliq. The results of the evaluation on datasets demonstrate that the proposed
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method yields better clustering results in comparison to the existing methods.
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CHAPTER 4 FUTURE WORK
In the first part of this thesis, we proposed a novel approach that discovers candidate
drugs for repurposing. This approach first builds a drug-disease network by considering
all interactions between drug targets and disease-related genes in the context of signaling pathways. This network is integrated with gene-expression measurements to identify
drugs with new desired therapeutic effects. The results are assessed using a true gold
standard, that of the already FDA-approved drugs. The already FDA-approved drugs for a
given condition are the gold standard because such drugs successfully passed all the preclinical and clinical trials for that condition and were demonstrated to be efficacious in
each condition. We provided evidences that support the usefulness of the proposed candidates in treatment of the human diseases: idiopathic pulmonary fibrosis (IPF), non-small
cell lung cancer, prostate cancer, breast cancer. In all diseases, the proposed approach is
able to rank highly the approved drugs for the given conditions. For many of the proposed
repurposing candidates, there is significant preliminary evidence, as well as a number of
clinical trials in progress. Although our proposed framework is studied in the context of
drug repurposing, it also can be used to identify novel targets for FDA-approved drugs and
predicting their mechanism of action using the drug-disease networks constructed by the
proposed approach.
Second, we proposed a resampling-based clustering approach that solves one of the
most important challenges in the personalized medicine area, which is identification of cell
types from single cell data. The proposed pipeline can be used to analyze and understand
cellular heterogeneity and how this contributes to the biological system.
In particular, the proposed clustering framework can be used to analyze the impact
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of glaucoma on single retinal ganglion cells (RGCs) and study the RGC subtypes that are
more resilient and susceptible to glaucoma insult [262, 302].
As future work, one could identify driver genes (cell type signatures) that vary between
two or more clusters (cell types). The driver genes could be identified as genes that are
highly expressed in only one of the clusters and are able to distinguish one cluster from
the remaining clusters. Subsequently, one could use the impact analysis method [72] to
perform gene and pathway enrichment analysis using the discovered driver genes.
Next, we are interested in upgrading the proposed clustering framework to identify the
rare cell populations in data (e.g cancer stem cells). We will generate synthetic data with
rare cell types to evaluate the sensitivity our framework for rare cell type identification.
The proposed clustering framework on other data types (e.g mRNA, miRNA, and methylation data) can be used to distinguish between subgroups of patients (respondent vs.
non-respondents) as well as disease subtypes (aggressive vs. non-aggressive). In addition to subtypes/subgroups discovery, our framework can help to identify the biomarkers [233, 242, 14] of identified subtypes that can assign a new sample to the correct
subgroup/subtype [207].
The distinct subtypes of the same disease cause diverse drug responses [86]. As a
result, the treatment choices and the ultimate success for a disease highly depend on
its subtype [86, 125, 243]. As future work, one could perform our drug repurposing
framework by utilizing the subtypes identified by our clustering framework.
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The traditional drug discovery process is extremely slow and costly. More than 90% of
drugs fail to pass beyond the early stage of development and toxicity tests, and many of the
drugs that go through early phases of the clinical trials fail because of adverse reactions,
side effects, or lack of efficiency. In spite of unprecedented investments in research and
development (R&D), the number of new FDA-approved drugs remains low, reflecting the
limitations of the current R&D model. In this context, finding new disease indications for
existing drugs sidesteps these issues and can therefore increase the available therapeutic
choices at a fraction of the cost of new drug development. In this thesis, we introduce
a drug repurposing approach that takes advantage of prior knowledge of drug targets,
disease-related genes, and signaling pathways to construct a drug-disease network composed of the genes that are most likely perturbed by a drug. Systems biology can be used as
an effective platform in drug discovery and development by leveraging the understanding
of interactions between the different system components [34, 141, 216]. By performing a
system-level analysis on this network, our approach estimates the amount of perturbation
caused by drugs and diseases and discovers drugs with the potential desired effects on

136
the given disease. Next, we develop a stable clustering method that employs a bootstrap
approach to identify the stable clusters of cells. We show that strong patterns in single cell
data will remain despite small perturbations. The results, that are validated based on wellknown metrics, show that using this approach yields improvement in correctly identifying
the cell types, compared to other existing methods.
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